<?xml version="1.0" encoding="UTF-8"?>
<patent-document ucid="EP-2678453-A1" country="EP" doc-number="2678453" kind="A1" date="20140101" family-id="46721258" file-reference-id="267002" date-produced="20180826" status="corrected" lang="EN"><bibliographic-data><publication-reference fvid="146551614" ucid="EP-2678453-A1"><document-id><country>EP</country><doc-number>2678453</doc-number><kind>A1</kind><date>20140101</date><lang>EN</lang></document-id></publication-reference><application-reference ucid="EP-12749162-A" is-representative="NO"><document-id mxw-id="PAPP154825537" load-source="docdb" format="epo"><country>EP</country><doc-number>12749162</doc-number><kind>A</kind><date>20120227</date><lang>EN</lang></document-id><document-id mxw-id="PAPP175260694" load-source="docdb" format="original"><country>EP</country><doc-number>12749162.9</doc-number><date>20120227</date></document-id></application-reference><priority-claims><priority-claim mxw-id="PPC140448695" ucid="US-201161446993-P" load-source="docdb"><document-id format="epo"><country>US</country><doc-number>201161446993</doc-number><kind>P</kind><date>20110225</date></document-id></priority-claim><priority-claim mxw-id="PPC140453696" ucid="US-201161494031-P" load-source="docdb"><document-id format="epo"><country>US</country><doc-number>201161494031</doc-number><kind>P</kind><date>20110607</date></document-id></priority-claim><priority-claim mxw-id="PPC140447842" ucid="US-2012026794-W" linkage-type="W" load-source="docdb"><document-id format="epo"><country>US</country><doc-number>2012026794</doc-number><kind>W</kind><date>20120227</date></document-id></priority-claim></priority-claims><technical-data><classifications-ipcr><classification-ipcr mxw-id="PCL-2048004753" load-source="docdb">C12Q   1/70        20060101AFI20150601BHEP        </classification-ipcr></classifications-ipcr><classifications-cpc><classification-cpc mxw-id="PCL-1883398005" load-source="docdb" scheme="CPC">C12Q2600/156       20130101 LA20161029BHEP        </classification-cpc><classification-cpc mxw-id="PCL-1883398854" load-source="docdb" scheme="CPC">C12Q2600/106       20130101 LA20161029BHEP        </classification-cpc><classification-cpc mxw-id="PCL-1883404225" load-source="docdb" scheme="CPC">C12Q   1/703       20130101 FI20161029BHEP        </classification-cpc></classifications-cpc><invention-title mxw-id="PT132187326" lang="DE" load-source="patent-office">VERFAHREN UND ZUSAMMENSETZUNGEN ZUR BESTIMMUNG DER ANFÄLLIGKEIT VON VIREN FÜR INTEGRASEHEMMER</invention-title><invention-title mxw-id="PT132187327" lang="EN" load-source="patent-office">METHODS AND COMPOSITIONS FOR DETERMINING VIRUS SUSCEPTIBILITY TO INTEGRASE INHIBITORS</invention-title><invention-title mxw-id="PT132187328" lang="FR" load-source="patent-office">PROCÉDÉS ET COMPOSITIONS POUR DÉTERMINATION DE LA SUSCEPTIBILITÉ D'UN VIRUS À DES INHIBITEURS D'INTÉGRASE</invention-title></technical-data><parties><applicants><applicant mxw-id="PPAR918132454" load-source="docdb" sequence="1" format="epo"><addressbook><last-name>LAB CORP AMERICA HOLDINGS</last-name><address><country>US</country></address></addressbook></applicant><applicant mxw-id="PPAR918143833" load-source="docdb" sequence="1" format="intermediate"><addressbook><last-name>LABORATORY CORPORATION OF AMERICA HOLDINGS</last-name></addressbook></applicant><applicant mxw-id="PPAR918982769" load-source="patent-office" sequence="1" format="original"><addressbook><last-name>Laboratory Corporation of America Holdings</last-name><iid>101298130</iid><address><street>358 South Main Street</street><city>Burlington, North Carolina 27215</city><country>US</country></address></addressbook></applicant></applicants><inventors><inventor mxw-id="PPAR918165734" load-source="docdb" sequence="1" format="epo"><addressbook><last-name>HUANG WEI</last-name><address><country>US</country></address></addressbook></inventor><inventor mxw-id="PPAR918149217" load-source="docdb" sequence="1" format="intermediate"><addressbook><last-name>HUANG, WEI</last-name></addressbook></inventor><inventor mxw-id="PPAR918984130" load-source="patent-office" sequence="1" format="original"><addressbook><last-name>HUANG, WEI</last-name><address><street>777 Comet Drive</street><city>Foster City California 94404</city><country>US</country></address></addressbook></inventor><inventor mxw-id="PPAR918136512" load-source="docdb" sequence="2" format="epo"><addressbook><last-name>PETROPOULOS CHRISTOS JOHN</last-name><address><country>US</country></address></addressbook></inventor><inventor mxw-id="PPAR918168859" load-source="docdb" sequence="2" format="intermediate"><addressbook><last-name>PETROPOULOS, Christos John</last-name></addressbook></inventor><inventor mxw-id="PPAR918990429" load-source="patent-office" sequence="2" format="original"><addressbook><last-name>PETROPOULOS, Christos John</last-name><address><street>415 Garcia Avenue</street><city>Half Moon Bay California 94019</city><country>US</country></address></addressbook></inventor></inventors><agents><agent mxw-id="PPAR918992188" load-source="patent-office" sequence="1" format="original"><addressbook><last-name>Donald, Jenny Susan</last-name><suffix>et al</suffix><iid>101298670</iid><address><street>Forresters Skygarden Erika-Mann-Strasse 11</street><city>80636 München</city><country>DE</country></address></addressbook></agent></agents></parties><international-convention-data><pct-or-regional-filing-data ucid="US-2012026794-W"><document-id><country>US</country><doc-number>2012026794</doc-number><kind>W</kind><date>20120227</date><lang>EN</lang></document-id></pct-or-regional-filing-data><pct-or-regional-publishing-data ucid="WO-2012116371-A1"><document-id><country>WO</country><doc-number>2012116371</doc-number><kind>A1</kind><date>20120830</date><lang>EN</lang></document-id></pct-or-regional-publishing-data><designated-states><ep-contracting-states><country mxw-id="DS548937126" load-source="docdb">AL</country><country mxw-id="DS548921121" load-source="docdb">AT</country><country mxw-id="DS548937127" load-source="docdb">BE</country><country mxw-id="DS548839536" load-source="docdb">BG</country><country mxw-id="DS548937889" load-source="docdb">CH</country><country mxw-id="DS548817743" load-source="docdb">CY</country><country mxw-id="DS548921122" load-source="docdb">CZ</country><country mxw-id="DS548937128" load-source="docdb">DE</country><country mxw-id="DS548817744" load-source="docdb">DK</country><country mxw-id="DS548817745" load-source="docdb">EE</country><country mxw-id="DS548868668" load-source="docdb">ES</country><country mxw-id="DS548839537" load-source="docdb">FI</country><country mxw-id="DS548839538" load-source="docdb">FR</country><country mxw-id="DS548937129" load-source="docdb">GB</country><country mxw-id="DS548817746" load-source="docdb">GR</country><country mxw-id="DS548937130" load-source="docdb">HR</country><country mxw-id="DS548921123" load-source="docdb">HU</country><country mxw-id="DS548937890" load-source="docdb">IE</country><country mxw-id="DS548937131" load-source="docdb">IS</country><country mxw-id="DS548839539" load-source="docdb">IT</country><country mxw-id="DS548817747" load-source="docdb">LI</country><country mxw-id="DS548933076" load-source="docdb">LT</country><country mxw-id="DS548921124" load-source="docdb">LU</country><country mxw-id="DS548933077" load-source="docdb">LV</country><country mxw-id="DS548933082" load-source="docdb">MC</country><country mxw-id="DS548944877" load-source="docdb">MK</country><country mxw-id="DS548944882" load-source="docdb">MT</country><country mxw-id="DS548839540" load-source="docdb">NL</country><country mxw-id="DS548868669" load-source="docdb">NO</country><country mxw-id="DS548839541" load-source="docdb">PL</country><country mxw-id="DS548944883" load-source="docdb">PT</country><country mxw-id="DS548839542" load-source="docdb">RO</country><country mxw-id="DS548944884" load-source="docdb">RS</country><country mxw-id="DS548839543" load-source="docdb">SE</country><country mxw-id="DS548944885" load-source="docdb">SI</country><country mxw-id="DS548937891" load-source="docdb">SK</country><country mxw-id="DS548937892" load-source="docdb">SM</country><country mxw-id="DS548933083" load-source="docdb">TR</country></ep-contracting-states></designated-states></international-convention-data><office-specific-data><eptags><ep-no-a-document-published>*</ep-no-a-document-published></eptags></office-specific-data></bibliographic-data><abstract mxw-id="PA99619180" ref-ucid="WO-2012116371-A1" lang="EN" load-source="patent-office"><p num="0000">Methods and compositions for the efficient and accurate determination of HIV susceptibility to an integrase inhibitor and/or HIV replication capacity are provided. In certain aspects, the methods involve detecting in a biological sample a nucleic acid encoding an HIV integrase that comprises a primary mutation at codon 143, wherein the mutation at codon 143 does not encode arginine (R) or cysteine (C), and wherein the presence of the integrase-encoding nucleic acid in the biological sample indicates that the HIV has a decreased susceptibility to an integrase inhibitor or altered replication capacity relative to a reference HIV. In certain embodiments, the HIV also contains one or more secondary mutations in integrase. Also provided are methods for determining the selective advantage of a mutation or mutation profile based on the difficulty to create the mutation, and its effect on susceptibility to an integrase inhibitor or replication capacity.</p></abstract><abstract mxw-id="PA99818861" ref-ucid="WO-2012116371-A1" lang="EN" source="national office" load-source="docdb"><p>Methods and compositions for the efficient and accurate determination of HIV susceptibility to an integrase inhibitor and/or HIV replication capacity are provided. In certain aspects, the methods involve detecting in a biological sample a nucleic acid encoding an HIV integrase that comprises a primary mutation at codon 143, wherein the mutation at codon 143 does not encode arginine (R) or cysteine (C), and wherein the presence of the integrase-encoding nucleic acid in the biological sample indicates that the HIV has a decreased susceptibility to an integrase inhibitor or altered replication capacity relative to a reference HIV. In certain embodiments, the HIV also contains one or more secondary mutations in integrase. Also provided are methods for determining the selective advantage of a mutation or mutation profile based on the difficulty to create the mutation, and its effect on susceptibility to an integrase inhibitor or replication capacity.</p></abstract><abstract mxw-id="PA99619181" ref-ucid="WO-2012116371-A1" lang="FR" load-source="patent-office"><p num="0000">L'invention concerne des procédés et des compositions pour la détermination efficace et précise de la sensibilité du VIH à un inhibiteur d'intégrase et/ou de la capacité de réplication du VIH. Sous certains aspects, les procédés entraînent la détection, dans un échantillon biologique, d'un acide nucléique codant pour une intégrase du VIH qui comporte une mutation primaire au codon 143, la mutation au codon 143 ne codant pas pour une arginine (R) ou une cystéine (C), et la présence de l'acide nucléique codant pour l'intégrase dans l'échantillon biologique indiquant que le VIH présente une sensibilité diminuée à un inhibiteur d'intégrase ou une capacité de réplication modifiée par rapport à un VIH de référence. Dans certains modes de réalisation, le VIH contient également une ou plusieurs mutations secondaires dans l'intégrase. L'invention concerne également des procédés de détermination de l'avantage sélectif d'une mutation ou d'un profil de mutation, sur la base de la difficulté à créer la mutation, et son effet sur la sensibilité à un inhibiteur de l'intégrase ou sur la capacité de réplication.</p></abstract><abstract mxw-id="PA99818862" ref-ucid="WO-2012116371-A1" lang="FR" source="national office" load-source="docdb"><p>L'invention concerne des procédés et des compositions pour la détermination efficace et précise de la sensibilité du VIH à un inhibiteur d'intégrase et/ou de la capacité de réplication du VIH. Sous certains aspects, les procédés entraînent la détection, dans un échantillon biologique, d'un acide nucléique codant pour une intégrase du VIH qui comporte une mutation primaire au codon 143, la mutation au codon 143 ne codant pas pour une arginine (R) ou une cystéine (C), et la présence de l'acide nucléique codant pour l'intégrase dans l'échantillon biologique indiquant que le VIH présente une sensibilité diminuée à un inhibiteur d'intégrase ou une capacité de réplication modifiée par rapport à un VIH de référence. Dans certains modes de réalisation, le VIH contient également une ou plusieurs mutations secondaires dans l'intégrase. L'invention concerne également des procédés de détermination de l'avantage sélectif d'une mutation ou d'un profil de mutation, sur la base de la difficulté à créer la mutation, et son effet sur la sensibilité à un inhibiteur de l'intégrase ou sur la capacité de réplication.</p></abstract><description mxw-id="PDES50930134" ref-ucid="WO-2012116371-A1" lang="EN" load-source="patent-office"><!-- EPO <DP n="2"/>--><p id="p0001" num="0001"> METHODS AND COMPOSITIONS FOR DETERMINING VIRUS SUSCEPTIBILITY TO INTEGRASE INHIBITORS </p><p id="p0002" num="0002">CROSS REFERENCE TO RELATED APPLICATIONS </p><p id="p0003" num="0003"> The present application claims the benefit of priority to U.S. Provisional Application</p><p id="p0004" num="0004">No. 61/446,993 filed February 25, 201 1 and to U.S. Provisional Application No. 61/494,031 filed June 7, 2011. The entire contents of both of these applications are hereby incorporated by reference. FIELD OF THE INVENTION </p><p id="p0005" num="0005"> Embodiments of the present invention relate to methods and compositions for determining the susceptibility of a human immunodeficiency virus ("HIV") to an integrase inhibitor or for determining the replication capacity of an HIV. BACKGROUND OF THE INVENTION </p><p id="p0006" num="0006"> More than 60 million people have been infected with the human immunodeficiency virus ("HIV"), the causative agent of acquired immune deficiency syndrome ("AIDS"), since the early 1980s. HIV/AIDS is now the leading cause of death in sub-Saharan Africa, and is the fourth biggest killer worldwide. At the end of 2001 , an estimated 40 million people were living with HIV globally. </p><p id="p0007" num="0007"> Modern anti-HIV drugs target different stages of the HIV life cycle and a variety of enzymes essential for HIV's replication and/or survival. Amongst the drugs that have so far been approved for AIDS therapy are nucleoside reverse transcriptase inhibitors ("NRTIs") such as AZT, ddl, ddC, d4T, 3TC, FTC, and abacavir; nucleotide reverse transcriptase inhibitors such as tenofovir; non-nucleoside reverse transcriptase inhibitors ("NNRTIs") such as nevirapine, efavirenz, delavirdine, and etravirine; protease inhibitors ("Pis") such as saquinavir, ritonavir, indinavir, nelfinavir, amprenavir, lopinavir, atazanavir, tipranavir, and darunavir; fusion inhibitors, such as enfuvirtide; CCR5 co-receptor antagonist, such as maraviroc; and integrase inhibitors, such as raltegravir. </p><p id="p0008" num="0008"> Unfortunately, HIV has a high mutation rate, resulting in the rapid emergence of mutant HIV having reduced susceptibility to an antiviral therapeutic upon administration of such drug to infected individuals. This reduced susceptibility to a particular drug renders treatment with that drug ineffective for the infected individual. For this reason, it is important for practitioners to be able to monitor drug susceptibility in order to determine the 
<!-- EPO <DP n="3"/>-->
 most appropriate treatment regime for each infected individual in order to prevent eventual progression of chronic HIV infection to AIDS, or to treat acute AIDS in that individual. </p><p id="p0009" num="0009"> Therefore, there is a need for methods and compositions for the efficient and accurate determination of susceptibility to drugs targeting HIV polypeptides. This and other needs are provided by the present invention. </p><p id="p0010" num="0010">SUMMARY OF THE INVENTION </p><p id="p0011" num="0011"> The present application provides methods and compositions for the efficient and accurate determination of the susceptibility of an HIV to an integrase inhibitor and/or the replication capacity of an HIV. The application also provides methods and compositions for determining the selective advantage of an integrase mutation or mutation profile. </p><p id="p0012" num="0012"> In certain aspects, methods are provided for determining the susceptibility of a human immunodeficiency virus (HIV) to an integrase inhibitor, comprising the steps of detecting in a biological sample from a patient infected with HIV a nucleic acid encoding an HIV integrase that comprises a mutation at codon 143, wherein the mutation at codon 143 does not encode arginine (R) or cysteine (C), and wherein the presence of the integrase-encoding nucleic acid in the biological sample indicates that the patient's HIV has a decreased susceptibility to the integrase inhibitor relative to a reference HIV, thereby assessing viral susceptibility to the integrase inhibitor. In certain embodiments, the integrase inhibitor is raltegravir or elvitegravir. In certain embodiments, the mutation at codon 143 encodes histidine (H), glycine (G), and serine (S). </p><p id="p0013" num="0013"> In some embodiments, the integrase comprising a mutation at position 143 has a secondary mutation. In certain embodiments, the secondary mutation in integrase is at codon 72, codon 74, codon 92, codon 97, codon 138, codon 157, codon 163, codon 203, codon 230, or a combination thereof. In certain embodiments, the integrase comprises a mutation at position 143 and one mutation at codon 72, codon 74, codon 92, codon 97, codon 138, codon 157, codon 163, codon 203, or codon 230. In certain other embodiments, the integrase comprises a mutation at position 143 and two of codon 72, codon 74, codon 92, codon 97, codon 138, codon 157, codon 163, codon 203, or codon 230. In other embodiments, the integrase comprises a mutation at position 143 and three or more of codon 72, codon 74, codon 92, codon 97, codon 138, codon 157, codon 163, codon 203, or codon 230. In particular embodiments, the mutation at codon 72 encodes an isoleucine (I) residue. In certain embodiments, the mutation at codon 74 encodes a methionine (M) or isoleucine (I) 
<!-- EPO <DP n="4"/>-->
 residue. The mutation at codon 92 in certain embodiments encodes a glutamine (Q) or leucine (L) residue. In certain embodiments, the mutation at codon 97 encodes an alanine (A) residue. The mutation at codon 138 in some embodiments encodes an aspartic acid (D) residue. The mutation at codon 157 in certain embodiments encodes a glutamine (Q) residue. In certain embodiments, the mutation at codon 163 encodes an arginine (R) residue. The mutation at codon 203 in some embodiments encodes a methionine (M) residue. In some embodiments, the mutation at codon 230 encodes an arginine (R) residue. The reference HIV may be an HXB-2, NL4-3, IIIB, or SF2 population. </p><p id="p0014" num="0014"> In other aspects, methods for determining the susceptibility of a human immunodeficiency vims (HIV) to an integrase inhibitor are provided, comprising the steps of detecting in a biological sample from a patient infected with HIV a nucleic acid encoding an HIV integrase that comprises a mutation at codon 143, wherein the mutation at codon 143 does not encode arginine (R), and a mutation at codon 74 or codon 97, wherein the presence of the integrase-encoding nucleic acid in the biological sample indicates that the patient's HIV has a decreased susceptibility to the integrase inhibitor relative to a reference HIV, thereby assessing viral susceptibility to the integrase inhibitor. In some embodiments, the integrase inhibitor is raltegravir or elvitegravir. In certain embodiments, the mutation at codon 143 encodes an amino acid selected from the group consisting of histidine (H), glycine (G), and serine (S), the mutation at codon 74 encodes a methionine (M) or isoleucine (I) residue, and the mutation at codon 97 encodes an alanine (A) residue. In certain embodiments, the nucleic acid encoding the HIV integrase comprises mutations at both codon 74 and codon 97. </p><p id="p0015" num="0015"> In other aspects, methods for determining the susceptibility of a human immunodeficiency vims (HIV) to an integrase inhibitor, comprising detecting in a biological sample from a patient infected with HIV a nucleic acid encoding an HIV integrase that comprises a mutation at codon 143, wherein the mutation at codon 143 does not encode arginine (R), and a mutation at codon 230, wherein the presence of the integrase-encoding nucleic acid in the biological sample indicates that the patient's HIV has a decreased susceptibility to the integrase inhibitor relative to a reference HIV, thereby assessing viral susceptibility to the integrase inhibitor. In some embodiments, the integrase inhibitor is raltegravir or elvitegravir. In certain embodiments, the mutation at codon 143 encodes an amino acid selected from the group consisting of histidine (H), glycine (G), and serine (S), and the mutation at codon 230 encodes an arginine (R) residue. In some embodiments, the 
<!-- EPO <DP n="5"/>-->
 nucleic acid encoding the HIV integrase further comprises a mutation at codon 97. In certain embodiments, the mutation at codon 97 encodes an alanine (A) residue. </p><p id="p0016" num="0016"> In certain other aspects, methods are provided for determining the replication capacity of a human immunodeficiency virus (HIV), comprising the steps of detecting in a biological sample from a patient infected with HIV a nucleic acid encoding an HIV integrase that comprises a mutation at codon 143, wherein the mutation at codon 143 does not encode arginine (R) or cysteine (C), and a mutation at codon 97, wherein the presence of the integrase-encoding nucleic acid in the biological sample indicates that the patient's HIV has a decreased replication capacity relative to a reference HIV, thereby assessing viral replication capacity. In certain embodiments, the mutation at codon 143 encodes an amino acid selected from the group consisting of histidine (H), glycine (G), and serine (S). In certain embodiments, the mutation at codon 97 is an alanine (A) residue. </p><p id="p0017" num="0017"> In other aspects, methods for determining the selective advantage of an integrase mutation or mutation profile are provided. These methods comprise the steps of determining the number of nucleotide substitutions in an integrase-encoding nucleic acid at codon 143 that are required to convert the codon encoding tyrosine to a codon encoding arginine, cysteine, histidine, glycine, or serine; determining the reduction in susceptibility to an integrase inhibitor that is conferred by the amino acid substitution at position 143; determining the impact of amino acid substitutions at position 143 on replication capacity; determining the number of secondary mutations and their impact on susceptibility to the integrase inhibitor, replication capacity, or both susceptibility and replication capacity; and determining the selective advantage of the mutation or the mutation profile, wherein the fewer the number of nucleotide substitutions required for the amino acid substitution, the higher the reduction of the susceptibility to the integrase inhibitor, the lower the impact on replication capacity, and the fewer the number of secondary mutations required to achieve the reduction in susceptibility to the integrase inhibitor, the greater the selective advantage for the mutation or mutation profile, thereby determining the selective advantage for the mutation or mutation profile. In some embodiments, the integrase inhibitor is raltegravir or elvitegravir. BRIEF DESCRIPTION OF THE FIGURES </p><p id="p0018" num="0018"> Non-limiting embodiments of the methods of the invention are exemplified in the following figures. 
<!-- EPO <DP n="6"/>-->
 Figure 1 is a table showing the amino acid substitutions identified at position 143 of integrase in each of one hundred sixteen virus samples. The number of population samples that had a single amino acid substitution present at position 143 and that did not have an amino acid substitution at position 148 or 155 are listed in the top panel. The number of population samples that had two or more amino acid substitution present at position 143 and that did not have an amino acid substitution at position 148 or 155 are listed in the second panel. The number of population samples that had at least a single amino acid substitution present at position 143 and that also had an amino acid substitution at position 155 are listed in the third panel. The number of population samples that had at least a single amino acid substitution present at position 143 and that also had an amino acid substitution at position 148 are listed in the bottom panel. </p><p id="p0019" num="0019"> Figure 2 is a table showing the clonal analysis of twenty patient samples. Forty to forty-eight clones from each virus population were included in this analysis. The samples indicated with an asterisk contain mixtures of Y143 mutation clones and N155H clones or Q148H clones. </p><p id="p0020" num="0020"> Figure 3 is a schematic diagram showing codon usage for different amino acid substitutions at position 143 of integrase. Two wild-type codons coding for tyrosine (Y), TAC (Panel A) and TAT (Panel B), are shown in the top hexagons. The substitutions shown in the middle hexagons require one nucleotide change from the tyrosine codon to create the codon for histidine, cysteine, or serine as shown. The substitutions in the bottom hexagons require two nucleotide changes from the tyrosine codon to create the codon for arginine or glycine as shown. Transitions are indicated by a bold arrow, and transversions are indicated by a regular arrow as well as an underline of the particular substitution. </p><p id="p0021" num="0021"> Figure 4 is a graph showing the fold changes in IC<sub>5</sub>0 (FC) in raltegravir (RAL) susceptibility of the seventy-six patient viruses having a single amino acid substitution at position 143 of integrase, as compared to the raltegravir susceptibility of an NL4-3 virus and determined by the PhenoSense<sup>®</sup> assay. Forty-four viruses had a Y143R substitution, and twenty-three had a Y143C substitution. Two viruses had a Y143H substitution (shown as the "x" in the Y143HGS column); three viruses had a Y143G substitution (shown as open squares in the Y143HGS column); and four viruses had a Y143S substitution (shown as filled squares in the Y143HGS column). The amino acid substitution present in the virus is shown on the x-axis, and the fold change in IC50 of raltegravir susceptibility relative to the reference virus is shown on the y-axis. 
<!-- EPO <DP n="7"/>-->
 Figure 5 is a table showing the fold change in IC50 in raltegravir (RAL FC) susceptibility of the six patient viruses having a single amino acid substitution at position 143 of integrase (histidine, glycine, or serine), as compared to the raltegravir susceptibility of an NL4-3 virus and determined by the PhenoSense<sup>®</sup> assay. The substitution at position 143 is shown with an underline. The table also identifies other substitutions present in the integrase coding region from the patient virus as compared to an NL4-3 virus integrase. </p><p id="p0022" num="0022"> Figures 6A and 6B are graphs showing the number and type of secondary mutations present in patient viruses with various substitutions present at position 143 of integrase. In Figure 6A, the left bar in each pair of bars represents viruses that have an arginine present at position 143 of integrase (Y143R), and the right bar in each pair represents viruses that have a cysteine, histidine, glycine, or serine residue present at position 143 of integrase (Y143H/G/S). Figure 6A lists the number of secondary mutations present on the x-axis and the number of viruses on the y-axis. In Figure 6A, in the portion where four secondary mutations are indicated, the left panel is not present. In Figure 6B, the left bar in each pair of bars represents viruses that have an arginine present at position 143 of integrase (Y143R), the middle bar represents viruses that have a cysteine at position 143 of integrase (Y143C), and the right bar in each pair represents viruses that have a cysteine, histidine, glycine, or serine residue present at position 143 of integrase (Y143C/H/G/S). Figure 6B shows the particular secondary mutation in integrase present on the x-axis versus the percentage of viruses on the y-axis. In the E92Q portion of the graph, there are no Y143R viruses. In the E138K portion of the graph, there are no Y143C or Y143C/H/G/S viruses. In the S230R portion of the graph, there are no Y143R viruses. </p><p id="p0023" num="0023"> Figure 7 is a table showing the frequency of secondary mutations among the seventy- six viruses identified with Y143R, Y143C, or Y143H/G/S mutations. The percentages shown in parentheses are with respect to the group (i. e. , the particular 143 mutation present). The average number of secondary mutations identified for each group is indicated in the far right, and the highest frequency of secondary mutations are indicated in bold font. The Y143C mutants had the highest average number of secondary mutations present. T97A and S230R were the most frequent secondary mutations present. </p><p id="p0024" num="0024"> Figures 8 A, 8B, and 8C are graphs showing the fold change (FC) in raltegravir susceptibility of site directed mutagenesis (SDM) viruses, as compared to the raltegravir susceptibility of an NL4-3 virus and determined by the PhenoSense assay. Figure 8A shows the fold change in raltegravir susceptibility for viruses having a single amino acid substitution 
<!-- EPO <DP n="8"/>-->
 at position 143 of integrase (histidine, cysteine, serine, glycine, or arginine). Figure 8B shows the fold change in raltegravir susceptibility for viruses having a single amino acid substitution at position 143 of integrase (histidine, cysteine, serine, glycine, or arginine), as well as a substitution of alanine at position 97 of integrase (T97A). Figure 8C shows the fold change in raltegravir susceptibility for viruses having a cysteine substitution at position 143 of integrase, as well as one or more secondary mutations (at positions 97, 163, 203, 74, 230, or 92 of the integrase) as listed on the x axis. </p><p id="p0025" num="0025"> Figure 9 is a table showing the effects of substitutions at position 143 of integrase and secondary mutations on RAL susceptibility. The substitution at position 143 of integrase is shown across the top of the table, and the total mutations present are shown in the first column. The values shown are the fold change in IC<sub>5</sub>o of the site directed mutants containing the listed mutations. </p><p id="p0026" num="0026"> Figures 10A, 10B, IOC, and 10D are graphs showing the effect of Y143 mutations with or without secondary mutations on viral fitness or replication capacity of the viruses. Each graph shows a serial drug dilution on the x axis (low concentration on the left to high concentration on the right) plotted against the ratio of relative luciferase units (RLU) of the mutant (MT) to the wild type (WT) virus on the y axis. The mutations present in the integrase are indicated (Y143C (diamonds), Y143H (gray asterisks), Y143G (gray triangles), Y143R (black triangles), and Y143S (black asterisks)). Panel A shows the viral fitness of viruses with single mutations at Y143. Panels B, C, and D show the viral fitness of viruses with mutations at Y143 as well as one or more secondary mutation (T97A (Panel B), S230R (Panel C), or both T97A and S230R (Panel D)). </p><p id="p0027" num="0027"> Figures 1 1A and 1 1B are graphs showing the cross-resistance pattern of patient- derived viruses to raltegravir (RAL) and elvitegravir (EVG). In Figure 1 1 A, the fold change in raltegravir susceptibility (RAL FC, x axis) is plotted against the fold change in elvitegravir susceptibility (EVG FC, y axis). In Figure 1 IB, the fold change decrease in susceptibility (FC in IC<sub>5</sub>o) was plotted for both RAL and EVG as shown. </p><p id="p0028" num="0028">DETAILED DESCRIPTION OF THE INVENTION </p><p id="p0029" num="0029"> The present invention provides, inter alia, methods for determining the susceptibility to an anti-HIV drug or replication capacity of an HIV infecting a patient. The methods, and compositions useful in performing the methods, are described extensively below. </p><p id="p0030" num="0030">Definitions and Abbreviations 
<!-- EPO <DP n="9"/>-->
 The following terms are herein defined as they are used in this application: </p><p id="p0031" num="0031"> "IN" is an abbreviation for "integrase." </p><p id="p0032" num="0032"> "PCR" is an abbreviation for "polymerase chain reaction." </p><p id="p0033" num="0033"> "HIV" is an abbreviation for human immunodeficiency virus. In preferred embodiments, HIV refers to HIV type 1. </p><p id="p0034" num="0034"> The amino acid notations used herein for the twenty genetically encoded L-amino acids are conventional and are as follows: </p><p id="p0035" num="0035"> TABLE 1 </p><p id="p0036" num="0036"><img id="imgf000009_0001" he="108" wi="165" file="imgf000009_0001.tif" img-format="tif" img-content="table" orientation="portrait" inline="yes"/></p><p id="p0037" num="0037">Unless noted otherwise, when polypeptide sequences are presented as a series of one- letter and/or three-letter abbreviations, the sequences are presented in the amino to carboxy terminal (N—C) direction, in accordance with common practice. Individual amino acids in a sequence are represented herein as AN, wherein A is the standard one letter symbol for the amino acid in the sequence, and N is the position in the sequence. Mutations are represented herein as AiNA<sub>2</sub>, wherein Ai is the standard one letter symbol for the amino acid in the reference protein sequence, A<sub>2</sub> is the standard one letter symbol for the amino acid in the mutated protein sequence, and N is the position in the amino acid sequence. For example, a G25M mutation represents a change from glycine to methionine at amino acid position 25. Mutations may also be represented herein as NA<sub>2</sub>, wherein N is the position in the amino acid 
<!-- EPO <DP n="10"/>-->
 sequence and A<sub>2</sub> is the standard one letter symbol for the amino acid in the mutated protein sequence {e.g., 25M, for a change from the wild-type amino acid to methionine at amino acid position 25). Additionally, mutations may also be represented herein as AjNX, wherein A<sub>\</sub> is the standard one letter symbol for the amino acid in the reference protein sequence, N is the position in the amino acid sequence, and X indicates that the mutated amino acid can be any amino acid (e.g., G25X represents a change from glycine to any amino acid at amino acid position 25). This notation is typically used when the amino acid in the mutated protein sequence is not known, if the amino acid in the mutated protein sequence could be any amino acid, except that found in the reference protein sequence, or if the amino acid in the mutated position is observed as a mixture of two or more amino acids at that position. The amino acid positions are numbered based on the full-length sequence of the protein from which the region encompassing the mutation is derived. Representations of nucleotides and point mutations in DNA sequences are analogous. In addition, mutations may also be represented herein as AiNA<sub>2</sub>A<sub>3</sub>A<sub>4</sub>, for example, wherein Ai is the standard one letter symbol for the amino acid in the reference protein sequence, N is the position in the amino acid sequence, and A<sub>2</sub>, A3, and A<sub>4</sub> are the standard one letter symbols for the amino acids that may be present in the mutated protein sequences. </p><p id="p0038" num="0038"> The abbreviations used throughout the specification to refer to nucleic acids comprising specific nucleobase sequences are the conventional one-letter abbreviations. Thus, when included in a nucleic acid, the naturally occurring encoding nucleobases are abbreviated as follows: adenine (A), guanine (G), cytosine (C), thymine (T) and uracil (U). Unless specified otherwise, single-stranded nucleic acid sequences that are represented as a series of one-letter abbreviations, and the top strand of double-stranded sequences, are presented in the 5'→3' direction. </p><p id="p0039" num="0039"> As used herein, the phrase "phenotypic assay" is a test that measures a phenotype of a particular virus, such as, for example, HIV, or a population of viruses, such as, for example, the population of HIV infecting a subject. The phenotypes that can be measured include, but are not limited to, the resistance or susceptibility of a virus, or of a population of viruses, to a specific chemical or biological anti-viral agent or that measures the replication capacity of a virus. </p><p id="p0040" num="0040"> As used herein, a "genotypic assay" is an assay that determines a genotype of an organism, a part of an organism, a population of organisms, a gene, a part of a gene, or a population of genes. Typically, a genotypic assay involves determination of the nucleic acid 
<!-- EPO <DP n="11"/>-->
 sequence of the relevant gene or genes. Such assays are frequently performed in HIV to establish, for example, whether certain mutations are associated with reductions in drug susceptibility (resistance) or hyper-susceptibility, or altered replication capacity are present. </p><p id="p0041" num="0041"> As used herein, the term "mutation" refers to a change in an amino acid sequence or in a corresponding nucleic acid sequence relative to a reference nucleic acid or polypeptide. For embodiments of the invention comprising a nucleic acid encoding HIV integrase, the reference nucleic acid encoding integrase is the integrase coding sequence present in NL4-3 HIV (GenBank Accession No. AF324493). In certain embodiments, the standard laboratory viral segment comprises a nucleic acid sequence from HIV strain IIIB. In certain embodiments, the IIIB sequence is disclosed as GenBank Accession No. U 12055. Likewise, the reference integrase polypeptide is that encoded by the NL4-3 HIV sequence. Although the amino acid sequence of a peptide can be determined directly by, for example, Edman degradation or mass spectroscopy, more typically, the amino sequence of a peptide is inferred from the nucleotide sequence of a nucleic acid that encodes the peptide. Any method for determining the sequence of a nucleic acid known in the art can be used, for example, Maxam-Gilbert sequencing (Maxam et al, 1980, Methods in Enzymology 65:499), dideoxy sequencing (Sanger et al, 1977, Proc. Natl. Acad. Sci. USA 74:5463) or hybridization-based approaches (see e.g., Sambrook et al, 2001, Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory, 3.sup.rd ed., NY; and Ausubel et al, 1989, Current Protocols in Molecular Biology, Greene Publishing Associates and Wiley Interscience, NY). As used herein, the terms "position" and "codon" are used interchangeably to refer to a particular amino acid in the sequence. </p><p id="p0042" num="0042"> As used herein, the term "mutant" refers to a virus, gene, or protein having a sequence that has one or more changes relative to a reference virus, gene, or protein. The terms "peptide," "polypeptide," and "protein" are used interchangeably throughout. Similarly, the terms "polynucleotide," "oligonucleotide," and "nucleic acid" are used interchangeably throughout. </p><p id="p0043" num="0043"> The term "wild-type" is used herein to refer to a viral genotype that does not comprise a mutation known to be associated with changes in drug susceptibility (reductions or increases) or replication capacity. </p><p id="p0044" num="0044"> As used herein, the term "susceptibility" refers to a virus's response to a particular drug. A virus that has decreased or reduced susceptibility to a drug may be resistant to the drug or may be less vulnerable to treatment with the drug. By contrast, a virus that has 
<!-- EPO <DP n="12"/>-->
 increased or enhanced susceptibility (hyper-susceptibility) to a drug is more vulnerable to treatment with the drug. </p><p id="p0045" num="0045"> The term "ICso" refers to the concentration of drug in the sample needed to suppress the reproduction of the disease causing microorganism (e.g. , HIV) by 50%. </p><p id="p0046" num="0046"> As used herein, the term "fold change" is a numeric comparison of the drug susceptibility of a patient virus and a drug-sensitive reference virus. For example, the ratio of a mutant HIV IC50 to the drug-sensitive reference HIV IC<sub>5</sub>0 is a fold change. A fold change of 1.0 indicates that the patient virus exhibits the same degree of drug susceptibility as the drug-sensitive reference virus. A fold change less than 1 indicates the patient virus is more sensitive than the drug-sensitive reference virus. A fold change greater than 1 indicates the patient virus is less susceptible than the drug-sensitive reference virus. A fold change equal to or greater than the clinical cutoff value means the patient virus has a lower probability of response to that drug. A fold change less than the clinical cutoff value means the patient virus is sensitive to that drug. </p><p id="p0047" num="0047"> The phrase "clinical cutoff value" refers to a specific point at which drug sensitivity ends. It is defined by the drug susceptibility level at which a patient's probability of treatment failure with a particular drug significantly increases. The cutoff value is different for different anti-viral agents, as determined in clinical studies. Clinical cutoff values are determined in clinical trials by evaluating resistance and outcomes data. Phenotypic drug susceptibility is measured at treatment initiation. Treatment response, such as change in viral load, is monitored at predetermined time points through the course of the treatment. The drug susceptibility is correlated with treatment response, and the clinical cutoff value is determined by susceptibility levels associated with treatment failure (statistical analysis of overall trial results). </p><p id="p0048" num="0048"> A virus may have an "increased likelihood of having reduced susceptibility" to an anti-viral treatment if the virus has a property, for example, a mutation, that is correlated with a reduced susceptibility to the anti-viral treatment. A property of a virus is correlated with a reduced susceptibility if a population of viruses having the property is, on average, less susceptible to the anti-viral treatment than an otherwise similar population of viruses lacking the property. Thus, the correlation between the presence of the property and reduced susceptibility need not be absolute, nor is there a requirement that the property is necessary (i.e. , that the property plays a causal role in reducing susceptibility) or sufficient (i. e. , that the presence of the property alone is sufficient) for conferring reduced susceptibility. 
<!-- EPO <DP n="13"/>-->
 The term "% sequence homology" is used interchangeably herein with the terms "% homology," "%&gt; sequence identity," and "% identity" and refers to the level of amino acid sequence identity between two or more peptide sequences, when aligned using a sequence alignment program. For example, as used herein, 80% homology means the same thing as 80% sequence identity determined by a defined algorithm, and accordingly a homologue of a given sequence has greater than 80% sequence identity over a length of the given sequence. Exemplary levels of sequence identity include, but are not limited to, 60, 70, 80, 85, 90, 95, 98%o, or more sequence identity to a given sequence. </p><p id="p0049" num="0049"> Exemplary computer programs which can be used to determine identity between two sequences include, but are not limited to, the suite of BLAST programs, e.g., BLASTN, BLASTX, and TBLASTX, BLASTP and TBLASTN, publicly available on the Internet at http://www.ncbi.nlm.nih.gov/BLAST/. See also Altschul et al , 1990, J. Mol. Biol. 215:403- 10 (with special reference to the published default setting, i.e. , parameters w=4, t=17) and Altschul et al, 1997, Nucleic Acids Res., 25 :3389-3402. Sequence searches are typically carried out using the BLASTP program when evaluating a given amino acid sequence relative to amino acid sequences in the GenBank Protein Sequences and other public databases. The BLASTX program is preferred for searching nucleic acid sequences that have been translated in all reading frames against amino acid sequences in the GenBank Protein Sequences and other public databases. Both BLASTP and BLASTX are run using default parameters of an open gap penalty of 1 1.0, and an extended gap penalty of 1.0, and utilize the BLOSUM-62 matrix. See Altschul, et al, 1997. </p><p id="p0050" num="0050"> A preferred alignment of selected sequences in order to determine "% identity" between two or more sequences, is performed using for example, the CLUSTAL-W program in MacVector version 6.5, operated with default parameters, including an open gap penalty of 10.0, an extended gap penalty of 0.1 , and a BLOSUM 30 similarity matrix. </p><p id="p0051" num="0051"> The term "polar amino acid" refers to a hydrophilic amino acid having a side chain that is uncharged at physiological pH, but which has at least one bond in which the pair of electrons shared in common by two atoms is held more closely by one of the atoms. Genetically encoded polar amino acids include Asn (N), Gin (Q), Ser (S), and Thr (T). </p><p id="p0052" num="0052"> "Nonpolar amino acid" refers to a hydrophobic amino acid having a side chain that is uncharged at physiological pH and which has bonds in which the pair of electrons shared in common by two atoms is generally held equally by each of the two atoms (i.e., the side chain 
<!-- EPO <DP n="14"/>-->
 is not polar). Genetically encoded apolar amino acids include Ala (A), Gly (G), lie (I), Leu (L), Met (M), and Val (V). </p><p id="p0053" num="0053"> "Hydrophilic amino acid" refers to an amino acid exhibiting a hydrophobicity of less than zero according to the normalized consensus hydrophobicity scale of Eisenberg et al. , 1984, J. Mol. Biol. 179: 125-142. Genetically encoded hydrophilic amino acids include Arg (R), Asn (N), Asp (D), Glu (E), Gin (Q), His (H), Lys (K), Ser (S), and Thr (T). </p><p id="p0054" num="0054"> "Hydrophobic amino acid" refers to an amino acid exhibiting a hydrophobicity of greater than zero according to the normalized consensus hydrophobicity scale of Eisenberg et al, 1984, J. Mol. Biol. 179: 125-142. Genetically encoded hydrophobic amino acids include Ala (A), Gly (G), He (I), Leu (L), Met (M), Phe (F), Pro (P), Trp (W), Tyr (Y), and Val (V). </p><p id="p0055" num="0055"> "Acidic amino acid" refers to a hydrophilic amino acid having a side chain pK value of less than 7. Acidic amino acids typically have negatively charged side chains at physiological pH due to loss of a hydrogen ion. Genetically encoded acidic amino acids include Asp (D) and Glu (E). </p><p id="p0056" num="0056"> "Basic amino acid" refers to a hydrophilic amino acid having a side chain pK value of greater than 7. Basic amino acids typically have positively charged side chains at physiological pH due to association with hydronium ion. Genetically encoded basic amino acids include Arg (R), His (H), and Lys (K). </p><p id="p0057" num="0057"> The term "resistance test vector," as used herein, refers to one or more nucleic acid comprising a patient-derived segment and an indicator gene. In the case where the resistance test vector comprises more than one nucleic acid, the patient-derived segment may be contained in one nucleic acid and the indicator gene in a different nucleic acid. For example, the indicator gene and the patient-derived segment may be in a single vector, may be in separate vectors, or the indicator gene and/or patient-derived segment may be integrated into the genome of a host cell. The DNA or RNA of a resistance test vector may thus be contained in one or more DNA or RNA molecules. The term "patient-derived segment," as used herein, refers to one or more nucleic acids that comprise an HIV nucleic acid sequence corresponding to a nucleic acid sequence of an HIV infecting a patient, where the nucleic acid sequence encodes an HIV gene product that is the target of an anti-HIV drug. A "patient- derived segment" can be prepared by an appropriate technique known to one of skill in the art, including, for example, molecular cloning or polymerase chain reaction (PCR) amplification from viral DNA or complementary DNA (cDNA) prepared from viral RNA, present in the cells {e.g. , peripheral blood mononuclear cells, PBMC), serum, or other bodily 
<!-- EPO <DP n="15"/>-->
 fluids of infected patients. A "patient-derived segment" is preferably isolated using a technique where the HIV infecting the patient is not passed through culture subsequent to isolation from the patient, or if the virus is cultured, then by a minimum number of passages to reduce or essentially eliminate the selection of mutations in culture. The term "indicator or indicator gene," as used herein, refers to a nucleic acid encoding a protein, DNA structure, or RNA structure that either directly or through a reaction gives rise to a measurable or noticeable aspect, e.g. , a color or light of a measurable wavelength or, in the case of DNA or RNA used as an indicator, a change or generation of a specific DNA or RNA structure. A preferred indicator gene is luciferase. </p><p id="p0058" num="0058">Methods of Determining Susceptibility to an Integrase Inhibitor </p><p id="p0059" num="0059"> In certain aspects, the present invention provides a method for determining the susceptibility of a human immunodeficiency virus (HIV) to an integrase inhibitor. In some embodiments, the integrase inhibitor is raltegravir or elvitegravir. The methods described herein may be applied to the analysis of gene activity from any source. For example, in certain embodiments, the methods may be used to analyze gene activity from a biological sample obtained from an individual, a cell culture sample, or a sample obtained from plants, insects, yeast, or bacteria. In certain embodiments, the sample may come from a virus. In certain embodiments, the virus is an HIV-1. </p><p id="p0060" num="0060"> In certain aspects, the present invention provides a method for determining the susceptibility of a human immunodeficiency virus (HIV) to an integrase inhibitor, comprising the steps of detecting in a biological sample from a patient infected with HIV a nucleic acid encoding an HIV integrase that comprises a mutation at codon 143, wherein the mutation at codon 143 does not encode arginine (R) or cysteine (C), and wherein the presence of the integrase-encoding nucleic acid in the biological sample indicates that the patient's HIV has a decreased susceptibility to the integrase inhibitor relative to a reference HIV, thereby assessing viral susceptibility to the integrase inhibitor. In some embodiments, the integrase inhibitor is raltegravir or elvitegravir. In certain embodiments, the mutation at codon 143 encodes an amino acid selected from the group consisting of histidine (H), glycine (G), and serine (S). </p><p id="p0061" num="0061"> In some embodiments, the integrase comprising a mutation at position 143 comprises a secondary mutation. In certain embodiments, the secondary mutation in integrase is at codon 72, codon 74, codon 92, codon 97, codon 138, codon 157, codon 163, codon 203, 
<!-- EPO <DP n="16"/>-->
 codon 230, or a combination thereof. In certain embodiments, the integrase comprises a mutation at position 143 and one of the remaining listed positions. In certain other embodiments, the integrase comprises a mutation at position 143 and two of the remaining listed positions. In other embodiments, the integrase comprises a mutation at position 143 and three or more of the remaining listed positions. In particular embodiments, the mutation at codon 72 encodes an isoleucine (I) residue. In certain embodiments, the mutation at codon 74 encodes a methionine (M) or isoleucine (I) residue. The mutation at codon 92 in certain embodiments encodes a glutamine (Q) or leucine (L) residue. In certain embodiments, the mutation at codon 97 encodes an alanine (A) residue. The mutation at codon 138 in some embodiments encodes an aspartic acid (D) residue. The mutation at codon 157 in certain embodiments encodes a glutamine (Q) residue. In certain embodiments, the mutation at codon 163 encodes an arginine (R) residue. The mutation at codon 203 in some embodiments encodes a methionine (M) residue. In some embodiments, the mutation at codon 230 encodes an arginine (R) residue. The reference HIV may be an HXB-2, NL4-3, IIIB, or SF2 population. </p><p id="p0062" num="0062"> In other aspects, methods for determining the susceptibility of a human immunodeficiency virus (HIV) to an integrase inhibitor are provided, comprising the steps of detecting in a biological sample from a patient infected with HIV a nucleic acid encoding an HIV integrase that comprises a mutation at codon 143, wherein the mutation at codon 143 does not encode arginine (R), and a mutation at codon 74 or codon 97, wherein the presence of the integrase-encoding nucleic acid in the biological sample indicates that the patient's HIV has a decreased susceptibility to the integrase inhibitor relative to a reference HIV, thereby assessing viral susceptibility to the integrase inhibitor. In some embodiments, the integrase inhibitor is raltegravir or elvitegravir. In certain embodiments, the mutation at codon 143 encodes an amino acid selected from the group consisting of histidine (H), glycine (G), and serine (S), the mutation at codon 74 encodes a methionine (M) or isoleucine (I) residue, and the mutation at codon 97 encodes an alanine (A) residue. In some embodiments, the integrase-encoding nucleic acid comprises a mutation at both codon 74 and codon 97. </p><p id="p0063" num="0063"> In other aspects, methods for determining the susceptibility of a human immunodeficiency virus (HIV) to an integrase inhibitor, comprising detecting in a biological sample from a patient infected with HIV a nucleic acid encoding an HIV integrase that comprises a mutation at codon 143, wherein the mutation at codon 143 does not encode arginine (R), and a mutation at codon 230, wherein the presence of the integrase-encoding 
<!-- EPO <DP n="17"/>-->
 nucleic acid in the biological sample indicates that the patient's HIV has a decreased susceptibility to the integrase inhibitor relative to a reference HIV, thereby assessing viral susceptibility to the integrase inhibitor. In some embodiments, the integrase inhibitor is raltegravir or elvitegravir. In certain embodiments, the mutation at codon 143 encodes an amino acid selected from the group consisting of histidine (H), glycine (G), and serine (S), and the mutation at codon 230 encodes an arginine (R) residue. </p><p id="p0064" num="0064"> The present methods may involve either nucleic acid or amino acid sequence analysis. For example, in certain embodiments, the method is used to analyze amino acid sequences in a protein. However, the method may also be used to analyze changes in gene activity that can occur as a result of mutations in non-coding regions. In some embodiments, where the sequence data is a mutation, the sequence may be compared to a reference. For example, in one embodiment, and for the examples used herein, the reference HIV is NL4-3. </p><p id="p0065" num="0065"> A variety of methods known in the art may be used to analyze and characterize genes from various samples. For example, Applicants refer to, and incorporate by reference herein U.S. Patent No. 7,384,734 and U.S. Patent Publication No. 2004/0248084 in their entireties, and specifically those portions of the specification that refer to abbreviations, definitions, the virus and viral samples that may be used, methods to detect the presence or absence of mutations in a virus, and methods for measuring the phenotypic susceptibility of a mutant virus. </p><p id="p0066" num="0066"> Phenotypic Susceptibility Analysis </p><p id="p0067" num="0067"> In certain embodiments, methods for determining integrase inhibitor susceptibility of a particular virus involve culturing a host cell comprising a patient-derived segment and an indicator gene in the presence of the integrase inhibitor, measuring the activity of the indicator gene in the host cell; and comparing the activity of the indicator gene as measured with a reference activity of the indicator gene, wherein the difference between the measured activity of the indicator gene relative to the reference activity correlates with the susceptibility of the HIV to the integrase inhibitor, thereby determining the susceptibility of the HIV to the integrase inhibitor. In some embodiments, the integrase inhibitor is raltegravir or elvitegravir. In certain embodiments, the activity of the indicator gene depends on the activity of a polypeptide encoded by the patient-derived segment. In preferred embodiments, the patient-derived segment comprises a nucleic acid sequence that encodes integrase. In certain embodiments, the patient-derived segment is obtained from the HIV. 
<!-- EPO <DP n="18"/>-->
 In certain embodiments, the reference activity of the indicator gene is determined by determining the activity of the indicator gene in the absence of the integrase inhibitor. In certain embodiments, the reference activity of the indicator gene is determined by determining the susceptibility of a reference HIV to the integrase inhibitor. In certain embodiments, the reference activity is determined by performing a method of the invention with a standard laboratory viral segment. In certain embodiments, the standard laboratory viral segment comprises a nucleic acid sequence from HIV strain NL4-3 (GenBank Accession No. Ml 9921). In certain embodiments, the standard laboratory viral segment comprises a nucleic acid sequence from HIV strain IIIB. In certain embodiments, the IIIB sequence is disclosed as GenBank Accession No. U 12055. </p><p id="p0068" num="0068"> In certain embodiments, the HIV is determined to have reduced susceptibility to an integrase inhibitor such as raltegravir or elvitegravir. In certain embodiments, the HIV is determined to have increased susceptibility to an integrase inhibitor such as raltegravir or elvitegravir. In certain embodiments, the patient-derived segment comprises a polymerase (pol) gene, or a portion thereof. In certain embodiments, the patient-derived segment is about 1.8 kB in length. In certain embodiments, the patient-derived segment encodes integrase and the RNAse H domain of reverse transcriptase. In certain embodiments, the patient-derived segment is about 3.3 kB in length. In certain embodiments, the patient-derived segment encodes protease, reverse transcriptase, and integrase. In certain embodiments, the patient- derived segment has been prepared in a reverse transcription and a polymerase chain reaction (PCR) reaction or a PCR reaction alone. </p><p id="p0069" num="0069"> In certain embodiments, the method additionally comprises the step of infecting the host cell with a viral particle comprising the patient-derived segment and the indicator gene prior to culturing the host cell. </p><p id="p0070" num="0070"> In certain embodiments, the indicator gene is a luciferase gene. In certain embodiments, the indicator gene is a lacZ gene. In certain embodiments, the host cell is a human cell. In certain embodiments, the host cell is a human embryonic kidney cell. In certain embodiments, the host cell is a 293 cell. In certain embodiments, the host cell is a human T cell. In certain embodiments, the host cell is derived from a human T cell leukemia cell line. In certain embodiments, the host cell is a Jurkat cell. In certain embodiments, the host cell is a H9 cell. In certain embodiments, the host cell is a CEM cell. </p><p id="p0071" num="0071"> In another aspect, the invention provides a vector comprising a patient-derived segment and an indicator gene. In certain preferred embodiments, the patient-derived 
<!-- EPO <DP n="19"/>-->
 segment comprises a nucleic acid sequence that encodes HIV integrase. In certain embodiments, the activity of the indicator gene depends on the activity of the HIV integrase. </p><p id="p0072" num="0072"> In certain embodiments, the patient-derived segment comprises an HIV pol gene, or a portion thereof. In certain embodiments, the indicator gene is a functional indicator gene. In certain embodiments, indicator gene is a non-functional indicator gene. In certain embodiments, the indicator gene is a luciferase gene. </p><p id="p0073" num="0073"> In another aspect, the invention provides a packaging host cell that comprises a vector of the invention. In certain embodiments, the packaging host cell is a mammalian host cell. In certain embodiments, the packaging host cell is a human host cell. In certain embodiments, the packaging host cell is a human embryonic kidney cell. In certain embodiments, the packaging host cell is a 293 cell. In certain embodiments, the packaging host cell is derived from a human hepatoma cell line. In certain embodiments, the packaging host cell is a HepG2 cell. In certain embodiments, the packaging host cell is a Huh7 cell. </p><p id="p0074" num="0074"> In another aspect, the invention provides a method for determining whether an HIV infecting a patient is susceptible or resistant to an integrase inhibitor. In certain embodiments, the method comprises determining the susceptibility of the HIV to an integrase inhibitor according to a method of the invention, and comparing the determined susceptibility of the HIV to the integrase inhibitor with a standard curve of susceptibility of the HIV to the integrase inhibitor. In certain embodiments, a decrease in the susceptibility of the HIV to the integrase inhibitor relative to the standard curve indicates that the HIV is resistant to the integrase inhibitor. In certain embodiments, the amount of the decrease in susceptibility of the HIV to the integrase inhibitor indicates the degree to which the HIV is less susceptible to the integrase inhibitor. </p><p id="p0075" num="0075"> In another aspect, the invention provides a method for determining the progression or development of resistance of an HIV infecting a patient to an integrase inhibitor. In certain embodiments, the method comprises determining the susceptibility of the HIV to the integrase inhibitor at a first time according to a method of the invention; assessing the effectiveness of the integrase inhibitor according to a method of the invention at a later second time; and comparing the effectiveness of the integrase inhibitor assessed at the first and second time. In certain embodiments, a patient-derived segment is obtained from the patient at about the first time. In certain embodiments, a decrease in the susceptibility of the HIV to the integrase inhibitor at the later second time as compared to the first time indicates 
<!-- EPO <DP n="20"/>-->
 development or progression of resistance to the integrase inhibitor in the HIV infecting the patient. </p><p id="p0076" num="0076"> In another aspect, the present invention provides a method for determining the susceptibility of an HIV infecting a patient to an integrase inhibitor. In some embodiments, the integrase inhibitor is raltegravir or elvitegravir. In certain embodiments, the method comprises culturing a host cell comprising a patient-derived segment obtained from the HIV and an indicator gene in the presence of varying concentrations of the integrase inhibitor, measuring the activity of the indicator gene in the host cell for the varying concentrations of the integrase inhibitor; and determining the IC50 of the HIV to the integrase inhibitor, wherein the IC50 of the HIV to the integrase inhibitor indicates the susceptibility of the HIV to the integrase inhibitor. In certain embodiments, the activity of the indicator gene depends on the activity of a polypeptide encoded by the patient-derived segment. In certain embodiments, the patient-derived segment comprises a nucleic acid sequence that encodes integrase. In certain embodiments, the IC50 of the HIV can be determined by plotting the activity of the indicator gene observed versus the log of anti-HIV drug concentration. </p><p id="p0077" num="0077"> In still another aspect, the invention provides a method for determining the susceptibility of a population of HIV infecting a patient to an integrase inhibitor. In certain embodiments, the method comprises culturing a host cell comprising a plurality of patient- derived segments from the HIV population and an indicator gene in the presence of the integrase inhibitor, measuring the activity of the indicator gene in the host cell; and comparing the activity of the indicator gene as measured with a reference activity of the indicator gene, wherein the difference between the measured activity of the indicator gene relative to the reference activity correlates with the susceptibility of the HIV to the integrase inhibitor, thereby determining the susceptibility of the HIV to the integrase inhibitor. In certain embodiments, the activity of the indicator gene depends on the activity of a plurality of polypeptide encoded by the plurality of patient-derived segments. In certain embodiments, the patient-derived segment comprises a nucleic acid sequence that encodes integrase. In certain embodiments, the plurality of patient-derived segments is prepared by amplifying the patient-derived segments from a plurality of nucleic acids obtained from a sample from the patient. </p><p id="p0078" num="0078"> In yet another aspect, the present invention provides a method for determining the susceptibility of a population of HIV infecting a patient to an integrase inhibitor. In certain embodiments, the method comprises culturing a host cell comprising a plurality of patient- 
<!-- EPO <DP n="21"/>-->
 derived segments obtained from the population of HIV and an indicator gene in the presence of varying concentrations of the integrase inhibitor, measuring the activity of the indicator gene in the host cell for the varying concentrations of the integrase inhibitor; and determining the IC50 of the population of HIV to the anti-viral drug, wherein the IC50 of the population of HIV to the integrase inhibitor indicates the susceptibility of the population of HIV to the integrase inhibitor. In certain embodiments, the host cell comprises a patient-derived segment and an indicator gene. In certain embodiments, the activity of the indicator gene depends on the activity of a plurality of polypeptides encoded by the plurality of patient-derived segments. In certain embodiments, the plurality of patient-derived segments comprises a nucleic acid sequence that encodes integrase. In certain embodiments, the IC50 of the population of HIV can be determined by plotting the activity of the indicator gene observed versus the log of anti-HIV drug concentration. In certain embodiments, the plurality of patient-derived segments is prepared by amplifying the patient-derived segments from a plurality of nucleic acids obtained from a sample from the patient. </p><p id="p0079" num="0079"> Construction of a Resistance Test Vector </p><p id="p0080" num="0080"> In certain embodiments, the resistance test vector can be made by insertion of a patient-derived segment into an indicator gene viral vector. Generally, in such embodiments, the resistance test vectors do not comprise all genes necessary to produce a fully infectious viral particle. In certain embodiments, the resistance test vector can be made by insertion of a patient-derived segment into a packaging vector while the indicator gene is contained in a second vector, for example an indicator gene viral vector. In certain embodiments, the resistance test vector can be made by insertion of a patient-derived segment into a packaging vector while the indicator gene is integrated into the genome of the host cell to be infected with the resistance test vector. </p><p id="p0081" num="0081"> If a drug were to target more than one functional viral sequence or viral gene product, patient-derived segments comprising each functional viral sequence or viral gene product can be introduced into the resistance test vector. In the case of combination therapy, where two or more anti-HIV drugs targeting the same or two or more different functional viral sequences or viral gene products are being evaluated, patient-derived segments comprising each such functional viral sequence or viral gene product can be inserted in the resistance test vector. The patient-derived segments can be inserted into unique restriction sites or specified locations, called patient sequence acceptor sites, in the indicator gene viral vector or for example, a packaging vector depending on the particular construction selected 
<!-- EPO <DP n="22"/>-->
 Patient-derived segments can be incorporated into resistance test vectors using any of suitable cloning technique known by one of skill in the art without limitation. For example, cloning via the introduction of class II restriction sites into both the plasmid backbone and the patient-derived segments, which is preferred, or by uracil DNA glycosylase primer cloning. </p><p id="p0082" num="0082"> The patient-derived segment may be obtained by any method of molecular cloning or gene amplification, or modifications thereof, by introducing patient sequence acceptor sites, as described below, at the ends of the patient-derived segment to be introduced into the resistance test vector. In a preferred embodiment, a gene amplification method such as PCR can be used to incorporate restriction sites corresponding to the patient-sequence acceptor sites at the ends of the primers used in the PCR reaction. Similarly, in a molecular cloning method such as cDNA cloning, the restriction sites can be incorporated at the ends of the primers used for first or second strand cDNA synthesis, or in a method such as primer-repair of DNA, whether cloned or uncloned DNA, the restriction sites can be incorporated into the primers used for the repair reaction. The patient sequence acceptor sites and primers can be designed to improve the representation of patient-derived segments. Sets of resistance test vectors having designed patient sequence acceptor sites allows representation of patient- derived segments that could be underrepresented in one resistance test vector alone. </p><p id="p0083" num="0083"> Resistance test vectors can be prepared by modifying an indicator gene viral vector by introducing patient sequence acceptor sites, amplifying or cloning patient-derived segments and introducing the amplified or cloned sequences precisely into indicator gene viral vectors at the patient sequence acceptor sites. In certain embodiments, the resistance test vectors can be constructed from indicator gene viral vectors, which in turn can be derived from genomic viral vectors or subgenomic viral vectors and an indicator gene cassette, each of which is described below. Resistance test vectors can then be introduced into a host cell. Alternatively, in certain embodiments, a resistance test vector can be prepared by introducing patient sequence acceptor sites into a packaging vector, amplifying or cloning patient-derived segments and inserting the amplified or cloned sequences precisely into the packaging vector at the patient sequence acceptor sites and co-transfecting this packaging vector with an indicator gene viral vector. </p><p id="p0084" num="0084"> In one preferred embodiment, the resistance test vector may be introduced into packaging host cells together with packaging expression vectors, as defined below, to produce resistance test vector viral particles that are used in drug resistance and susceptibility tests that are referred to herein as a "particle-based test." In an alternative embodiment, the 
<!-- EPO <DP n="23"/>-->
 resistance test vector may be introduced into a host cell in the absence of packaging expression vectors to carry out a drug resistance and susceptibility test that is referred to herein as a "non-particle-based test." As used herein a "packaging expression vector" provides the factors, such as packaging proteins (e.g. , structural proteins such as core and envelope polypeptides), transacting factors, or genes required by replication-defective HIV. In such a situation, a replication-competent viral genome is enfeebled in a manner such that it cannot replicate on its own. This means that, although the packaging expression vector can produce the trans-acting or missing genes required to rescue a defective viral genome present in a cell containing the enfeebled genome, the enfeebled genome cannot rescue itself Such embodiments are particularly useful for preparing viral particles that comprise resistance test vectors which do not comprise all viral genes necessary to produce a fully infectious viral particle. </p><p id="p0085" num="0085"> In certain embodiments, the resistance test vectors comprise an indicator gene, though as described above, the indicator gene need not necessarily be present in the resistance test vector. Examples of indicator genes include, but are not limited to, the E. coli lacZ gene which encodes beta-galactosidase, the luc gene which encodes luciferase either from, for example, Photonis pyralis (the firefly) or Renilla reniformis (the sea pansy), the E. coli phoA gene which encodes alkaline phosphatase, green fluorescent protein and the bacterial CAT gene which encodes chloramphenicol acetyltransferase. A preferred indicator gene is firefly luciferase. Additional examples of indicator genes include, but are not limited to, secreted proteins or cell surface proteins that are readily measured by assay, such as radioimmunoassay (RIA), or fluorescent activated cell sorting (FACS), including, for example, growth factors, cytokines and cell surface antigens (e.g. growth hormone, 11-2 or CD4, respectively). Still other exemplary indicator genes include selection genes, also referred to as selectable markers. Examples of suitable selectable markers for mammalian cells are dihydrofolate reductase (DHFR), thymidine kinase, hygromycin, neomycin, zeocin or E. coli gpt. In the case of the foregoing examples of indicator genes, the indicator gene and the patient-derived segment are discrete, i.e. distinct and separate genes. In some cases, a patient-derived segment may also be used as an indicator gene. In one such embodiment in which the patient-derived segment corresponds to one or more HIV genes which is the target of an anti-HIV agent, one of the HIV genes may also serve as the indicator gene. For example, a viral protease gene may serve as an indicator gene by virtue of its ability to cleave a chromogenic substrate or its ability to activate an inactive zymogen which in turn cleaves a 
<!-- EPO <DP n="24"/>-->
 chromogenic substrate, giving rise in each case to a color reaction. In all of the above examples of indicator genes, the indicator gene may be either "functional" or "nonfunctional" but in each case the expression of the indicator gene in the target cell is ultimately dependent upon the action of the patient-derived segment. Generally, the activity of the indicator gene, e.g. , a functional property of the indicator gene such as emission of light or generation of a chromogenic substrate, can be monitored. However, the activity of an indicator gene can also be monitored by determining the amount of expression of the indicator gene using any convenient method known by one of skill in the art. </p><p id="p0086" num="0086"> In certain embodiments, the indicator gene may be capable of being expressed in a host cell transfected with a resistance test vector and a packaging expression vector, independent of the patient-derived segment, however the functional indicator gene cannot be expressed in the target host cell, as defined below, without the production of functional resistance test vector particles and their effective infection of the target host cell. In such embodiments, the indicator gene is referred to as a "functional indicator gene." In certain embodiments, the functional indicator gene cassette, comprising control elements and a gene encoding an indicator protein, is inserted into the indicator gene viral vector with the same or opposite transcriptional orientation as the native or foreign enhancer/promoter of the viral vector. </p><p id="p0087" num="0087"> In alternate embodiments, the indicator gene may be a "non-functional indicator gene" in that the indicator gene is not efficiently expressed in a packaging host cell transfected with the resistance test vector, until it is converted into a functional indicator gene through the action of one or more of the patient-derived segment products. An indicator gene can be rendered non-functional through genetic manipulation as described below. </p><p id="p0088" num="0088"> In certain embodiments, an indicator gene can be rendered non-functional due to the location of the promoter, in that, although the promoter is in the same transcriptional orientation as the indicator gene, it follows rather than precedes the indicator gene coding sequence. This misplaced promoter is referred to as a "permuted promoter." In addition to the permuted promoter, the orientation of the non-functional indicator gene is opposite to that of the native or foreign promoter/enhancer of the viral vector. Thus, the coding sequence of the non-functional indicator gene can be transcribed by neither the permuted promoter nor by the viral promoters. The non-functional indicator gene and its permuted promoter can be rendered functional by the action of one or more of the viral proteins. In one example of a non-functional indicator gene with a permuted promoter, a T7 phage RNA polymerase 
<!-- EPO <DP n="25"/>-->
 promoter (herein referred to as T7 promoter) can be placed in the 5' LTR in the same transcriptional orientation as the indicator gene. In such embodiments, indicator gene cannot be transcribed by the T7 promoter as the indicator gene cassette is positioned upstream of the T7 promoter. The non-functional indicator gene in the resistance test vector can be converted into a functional indicator gene by reverse transcriptase upon infection of the target cells, resulting from the repositioning of the T7 promoter by copying from the 5' LTR to the 3' LTR, relative to the indicator gene coding region. Following the integration of the repaired indicator gene into the target cell chromosome by HIV integrase, a nuclear T7 RNA polymerase expressed by the target cell can transcribe the indicator gene. </p><p id="p0089" num="0089"> A permuted promoter may be any eukaryotic or prokaryotic promoter which can be transcribed in the target host cell known to one of skill in the art without limitation. Preferably the promoter will be small in size to enable insertion in the viral genome without disturbing viral replication. More preferably, a promoter that is small in size and is capable of transcription by a single subunit RNA polymerase introduced into the target host cell, such as a bacteriophage promoter, can be used. Examples of such bacteriophage promoters and their cognate RNA polymerases include those of phages T7, T3 and Sp6. A nuclear localization sequence (NLS) may be attached to the RNA polymerase to localize expression of the RNA polymerase to the nucleus where they may be needed to transcribed the repaired indicator gene. Such an NLS may be obtained from any nuclear-transported protein such as the SV40 T antigen. If a phage RNA polymerase is employed, an internal ribosome entry site (IRES) such as the EMC virus 5' untranslated region (UTR) may be added in front of the indicator gene for translation of the transcripts which are generally uncapped. The permuted promoter itself can be introduced at any position within the 5' LTR that is copied to the 3' LTR during reverse transcription so long as LTR function is not disrupted, preferably within the U5 and R portions of the LTR, and most preferably outside of functionally important and highly conserved regions of U5 and R. Further, blocking sequences may be added at the ends of the resistance test vector should there be inappropriate expression of the non-functional indicator gene due to transfection artifacts (DNA concatenation). In the example of the permuted T7 promoter given above, such a blocking sequence may consist of a T7 transcriptional terminator, positioned to block readthrough transcription resulting from DNA concatenation, but not transcription resulting from repositioning of the permuted T7 promoter from the 5' LTR to the 3' LTR during reverse transcription. 
<!-- EPO <DP n="26"/>-->
 In other embodiments of a "nonfunctional indicator gene," an indicator gene can be rendered non-functional due to the relative location of the 5' and 3' coding regions of the indicator gene, in that the 3' coding region precedes rather than follows the 5' coding region. This misplaced coding region is referred to as a "permuted coding region." The orientation of the non-functional indicator gene may be the same or opposite to that of the native or foreign promoter/enhancer of the viral vector, as mRNA coding for a functional indicator gene will be produced in the event of either orientation. The non-functional indicator gene and its permuted coding region can be rendered functional by the action of one or more of the patient-derived segment products. An example of a non-functional indicator gene with a permuted coding region places a 5' indicator gene coding region with an associated promoter in the 3 ' LTR U3 region and a 3 ' indicator gene coding region in an upstream location of the HIV genome, with each coding region having the same transcriptional orientation as the viral LTRs. The 5' and 3' coding regions may also have associated splice donor and acceptor sequences, respectively, which may be heterologous or artificial splicing signals. The indicator gene cannot be functionally transcribed either by the associated promoter or viral promoters, as the permuted coding region prevents the formation of functionally spliced transcripts. The non-functional indicator gene in the resistance test vector is converted into a functional indicator gene by reverse transcriptase upon infection of the target cells, resulting from the repositioning of the 5' and 3' indicator gene coding regions relative to one another, by copying of the 3 ' LTR to the 5' LTR. Following transcription by the promoter associated with the 5' coding region, RNA splicing can join the 5' and 3' coding regions to produce a functional indicator gene product. </p><p id="p0090" num="0090"> In another embodiment of a "non-functional indicator gene," the indicator gene is rendered non-functional through use of an "inverted intron," i.e., an intron inserted into the coding sequence of the indicator gene with a transcriptional orientation opposite to that of the indicator gene. The overall transcriptional orientation of the indicator gene cassette including its own linked promoter can be opposite to that of the viral control elements, while the orientation of the artificial intron can be the same as the viral control elements. Transcription of the indicator gene by its own linked promoter does not lead to the production of functional transcripts, as the inverted intron cannot be spliced in this orientation. Transcription of the indicator gene by the viral control elements does, however, lead to the removal of the inverted intron by RNA splicing, although the indicator gene is still not functionally expressed as the resulting transcript has an antisense orientation. Following the reverse 
<!-- EPO <DP n="27"/>-->
 transcription of this transcript and integration of the resultant retroviral DNA, the indicator gene can be functionally transcribed using its own linked promoter as the inverted intron has been previously removed. In this case, the indicator gene itself may contain its own functional promoter with the entire transcriptional unit oriented opposite to the viral control elements. Thus the non-functional indicator gene is in the wrong orientation to be transcribed by the viral control elements and it cannot be functionally transcribed by its own promoter, as the inverted intron cannot be properly excised by splicing. However, transcription by the viral promoters (HIV LTR) results in the removal of the inverted intron by splicing. As a consequence of reverse transcription of the resulting spliced transcript and the integration of the resulting provirus into the host cell chromosome, the indicator gene can now be functionally transcribed by its own promoter. The inverted intron, consisting of a splice donor and acceptor site to remove the intron, is preferably located in the coding region of the indicator gene in order to disrupt translation of the indicator gene. The splice donor and acceptor may be any splice donor and acceptor. A preferred splice donor-receptor is the CMV IE splice donor and the splice acceptor of the second exon of the human alpha globin gene ("intron A"). </p><p id="p0091" num="0091"> As discussed above, a resistance test vector can be assembled from an indicator gene viral vector. As used herein, "indicator gene viral vector" refers to a vector(s) comprising an indicator gene and its control elements and one or more viral genes. The indicator gene viral vector can be assembled from an indicator gene cassette and a "viral vector," defined below. The indicator gene viral vector may additionally include an enhancer, splicing signals, polyadenylation sequences, transcriptional terminators, or other regulatory sequences. Additionally the indicator gene in the indicator gene viral vector may be functional or nonfunctional. In the event that the viral segments which are the target of the anti -viral drug are not included in the indicator gene viral vector, they can be provided in a second vector. An "indicator gene cassette" comprises an indicator gene and control elements, and, optionally, is configured with restriction enzyme cleavage sites at its ends to facilitate introduction of the cassette into a viral vector. A "viral vector" refers to a vector comprising some or all of the following: viral genes encoding a gene product, control sequences, viral packaging sequences, and in the case of a retrovirus, integration sequences. The viral vector may additionally include one or more viral segments, one or more of which may be the target of an anti-viral drug. Two examples of a viral vector which contain viral genes are referred to herein as an "genomic viral vector" and a "subgenomic viral vector." A "genomic viral 
<!-- EPO <DP n="28"/>-->
 vector" is a vector which may comprise a deletion of a one or more viral genes to render the virus replication incompetent, e.g., unable to express all of the proteins necessary to produce a fully infectious viral particle, but which otherwise preserves the mRNA expression and processing characteristics of the complete virus. In one embodiment for an HIV drug susceptibility and resistance test, the genomic viral vector comprises the HIV gag, pol, vif, vpr, tat, rev, vpu, and nef genes. In certain embodiments, some, most or all of env can be deleted. A "subgenomic viral vector" refers to a vector comprising the coding region of one or more viral genes which may encode the proteins that are the target(s) of the anti-viral drug. In a preferred embodiment, a subgenomic viral vector comprises the HIV pol gene, or a portion thereof. Two examples of proviral clones that can be used for viral vector construction are: HXB2 (Fisher et al., 1986 Nature 320:367-371) and NL4-3 (Adachi et αί , 1986, J. Virol., 59:284-291). In certain embodiments, the viral coding genes can be under the control of a native enhancer/promoter. In certain embodiments, the viral coding genes can be under the control of a foreign viral or cellular enhancer/promoter. In a preferred embodiment, the genomic or subgenomic viral coding regions can be under the control of the native enhancer/promoter of the HIV-LTR U3 region or the CMV immediate-early (IE) enhancer/promoter. In certain embodiments of an indicator gene viral vector that contains one or more viral genes which are the targets or encode proteins which are the targets of one or more anti-viral drug(s), the vector can comprise patient sequence acceptor sites. The patient- derived segments can be inserted in the patient sequence acceptor site in the indicator gene viral vector which is then referred to as the resistance test vector, as described above. </p><p id="p0092" num="0092"> "Patient sequence acceptor sites" are sites in a vector for insertion of patient-derived segments. In certain embodiments, such sites may be: 1) unique restriction sites introduced by site-directed mutagenesis into a vector; 2) naturally occurring unique restriction sites in the vector; or 3) selected sites into which a patient-derived segment may be inserted using alternative cloning methods (e.g. UDG cloning). In certain embodiments, the patient sequence acceptor site is introduced into the indicator gene viral vector by site-directed mutagenesis. The patient sequence acceptor sites can be located within or near the coding region of the viral protein which is the target of the anti-viral drug. The viral sequences used for the introduction of patient sequence acceptor sites are preferably chosen so that no change is made in the amino acid coding sequence found at that position. If a change is made in the amino acid coding sequence at the position, the change is preferably a conservative change. Preferably the patient sequence acceptor sites can be located within a relatively conserved 
<!-- EPO <DP n="29"/>-->
 region of the viral genome to facilitate introduction of the patient-derived segments. Alternatively, the patient sequence acceptor sites can be located between functionally important genes or regulatory sequences. Patient-sequence acceptor sites may be located at or near regions in the viral genome that are relatively conserved to permit priming by the primer used to introduce the corresponding restriction site into the patient-derived segment. To improve the representation of patient-derived segments further, such primers may be designed as degenerate pools to accommodate viral sequence heterogeneity, or may incorporate residues such as deoxyinosine (I) which have multiple base-pairing capabilities. Sets of resistance test vectors having patient sequence acceptor sites that define the same or overlapping restriction site intervals may be used together in the drug resistance and susceptibility tests to provide representation of patient-derived segments that contain internal restriction sites identical to a given patient sequence acceptor site, and would thus be underrepresented in either resistance test vector alone. </p><p id="p0093" num="0093"> Construction of the vectors of the invention employs standard ligation and restriction techniques which are well understood in the art. See, for example, Ausubel et al , 2005, Current Protocols in Molecular Biology Wiley—Interscience and Sambrook et al , 2001, Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory, N.Y. Isolated plasmids, DNA sequences, or synthesized oligonucleotides can be cleaved, tailored, and relegated in the form desired. The sequences of all DNA constructs incorporating synthetic DNA can be confirmed by DNA sequence analysis. See, for example, Sanger et al, 1977, PNAS USA 74:5463-5467. </p><p id="p0094" num="0094"> In addition to the elements discussed above, the vectors used herein may also contain a selection gene, also termed a selectable marker. In certain embodiments, the selection gene encodes a protein, necessary for the survival or growth of a host cell transformed with the vector. Examples of suitable selectable markers for mammalian cells include the dihydrofolate reductase gene (DHFR), the ornithine decarboxylase gene, the multi-drug resistance gene (mdr), the adenosine deaminase gene, and the glutamine synthase gene. When such selectable markers are successfully transferred into a mammalian host cell, the transformed mammalian host cell can survive if placed under selective pressure. There are two widely used distinct categories of selective regimes. The first category is based on a cell's metabolism and the use of a mutant cell line which lacks the ability to grow independent of a supplemented media. The second category is referred to as dominant selection which refers to a selection scheme used in any cell type and does not require the use 
<!-- EPO <DP n="30"/>-->
 of a mutant cell line. These schemes typically use a drug to arrest growth of a host cell. Those cells which have a novel gene would express a protein conveying drug resistance and would survive the selection. Examples of such dominant selection use the drugs neomycin (see Southern and Berg, 1982, J. Molec. Appl. Genet. 1 :327, mycophenolic acid (see Mulligan and Berg, 1980, Science 209: 1422, or hygromycin (see Sugden et al , 1985, Mol. Cell. Biol. 5:410-413. The three examples given above employ bacterial genes under eukaryotic control to convey resistance to the appropriate drug neomycin (G418 or genticin), xgpt (mycophenolic acid) or hygromycin, respectively. </p><p id="p0095" num="0095"> Host Cells </p><p id="p0096" num="0096"> In certain embodiments, the methods of the invention comprise culturing a host cell that comprises a patient-derived segment and an indicator gene. In certain embodiments, the host cells can be mammalian cells. Preferred host cells can be derived from human tissues and cells which are the principle targets of viral infection. Such host cells include, but are not limited to, human cells such as human T cells, monocytes, macrophage, dendritic cells, Langerhans cells, hematopoeitic stem cells or precursor cells, and the like. Human-derived host cells allow the anti-viral drug to enter the cell efficiently and be converted by the cellular enzymatic machinery into the metabolically relevant form of the anti-viral inhibitor. In some embodiments, host cells can be referred to herein as a "packaging host cells," "resistance test vector host cells," or "target host cells." A "packaging host cell" refers to a host cell that provides the transacting factors and viral packaging proteins required by the replication defective viral vectors used herein, such as, e.g. , the resistance test vectors, to produce resistance test vector viral particles. The packaging proteins may provide for expression of viral genes contained within the resistance test vector itself, a packaging expression vector(s), or both. A packaging host cell can be a host cell which is transfected with one or more packaging expression vectors and when transfected with a resistance test vector is then referred to herein as a "resistance test vector host cell" and is sometimes referred to as a packaging host cell/resistance test vector host cell. Preferred host cells for use as packaging host cells include 293 human embryonic kidney cells (Graham et al , 1977, J. Gen Virol. 36:59), BOSC23 (Pear et al , 1993, P.N.A.S. USA. 90:8392), and tsa54 and tsa201 cell lines (Heinzel et al, 1988, J. Virol. 62:3738). A "target host cell" refers to a cell to be infected by resistance test vector viral particles produced by the resistance test vector host cell in which expression or inhibition of the indicator gene takes place. Preferred host cells for use as target host cells include human T cell leukemia cell lines including Jurkat (ATCC TIB- 152), H9 
<!-- EPO <DP n="31"/>-->
 (ATCC HTB-176), CEM (ATCC CCL-1 19), HUT78 (ATCC T1 B-161), and derivatives thereof, and 293 cells. </p><p id="p0097" num="0097"> Unless otherwise provided, the method used herein for transformation of the host cells is the calcium phosphate co-precipitation method of Graham and van der Eb, 1973, Virology 52:456-457. Alternative methods for transfection include, but are not limited to, electroporation, the DEAE-dextran method, lipofection and biolistics. See, e.g. , Kriegler, 1990, Gene Transfer and Expression: A Laboratory Manual, Stockton Press. </p><p id="p0098" num="0098"> Host cells may be transfected with the expression vectors of the present invention and cultured in conventional nutrient media modified as is appropriate for inducing promoters, selecting transformants or amplifying genes. Host cells are cultured in F 12: DMEM (Gibco) 50:50 with added glutamine and without antibiotics. The culture conditions, such as temperature, pH and the like, are those previously used with the host cell selected for expression, and will be apparent to the ordinarily skilled artisan. </p><p id="p0099" num="0099"> Drug Susceptibility and Resistance Tests </p><p id="p0100" num="0100"> Drug susceptibility and resistance tests may be carried out in one or more host cells.</p><p id="p0101" num="0101">Viral drug susceptibility is determined as the concentration of the anti-viral agent at which a given percentage of indicator gene expression is inhibited (e.g. , the IC<sub>50</sub> for an anti-viral agent is the concentration at which 50% of indicator gene expression is inhibited). A standard curve for drug susceptibility of a given anti-viral drug can be developed for a viral segment that is either a standard laboratory viral segment or from a drug-naive patient (i.e. , a patient who has not received any anti-viral drug) using the method of this invention. Correspondingly, viral drug resistance can be determined by detecting a decrease in viral drug susceptibility for a given patient either by comparing the drug susceptibility to such a given standard or by making sequential measurement in the same patient over time, as determined by increased inhibition of indicator gene expression (i.e. decreased indicator gene expression). </p><p id="p0102" num="0102"> In certain embodiments, resistance test vector viral particles are produced by a first host cell (the resistance test vector host cell) that is prepared by transfecting a packaging host cell with the resistance test vector and packaging expression vector(s). The resistance test vector viral particles can then be used to infect a second host cell (the target host cell) in which the expression of the indicator gene is measured. Such a two cell system comprising a packaging host cell which is transfected with a resistance test vector, which is then referred to as a resistance test vector host cell, and a target cell are used in the case of either a functional 
<!-- EPO <DP n="32"/>-->
 or non-functional indicator gene. Functional indicator genes are efficiently expressed upon transfection of the packaging host cell, and thus infection of a target host cell with resistance test vector host cell supernatant is needed to accurately determine drug susceptibility. Nonfunctional indicator genes with a permuted promoter, a permuted coding region, or an inverted intron are not efficiently expressed upon transfection of the packaging host cell and thus the infection of the target host cell can be achieved either by co-cultivation by the resistance test vector host cell and the target host cell or through infection of the target host cell using the resistance test vector host cell supernatant. In the second type of drug susceptibility and resistance test, a single host cell (the resistance test vector host cell) also serves as a target host cell. The packaging host cells are transfected and produce resistance test vector viral particles and some of the packaging host cells also become the target of infection by the resistance test vector particles. Drug susceptibility and resistance tests employing a single host cell type are possible with viral resistance test vectors comprising a non-functional indicator gene with a permuted promoter, a permuted coding region, or an inverted intron. Such indicator genes are not efficiently expressed upon transfection of a first cell, but are only efficiently expressed upon infection of a second cell, and thus provide an opportunity to measure the effect of the anti-viral agent under evaluation. In the case of a drug susceptibility and resistance test using a resistance test vector comprising a functional indicator gene, neither the co-cultivation procedure nor the resistance and susceptibility test using a single cell type can be used for the infection of target cells. A resistance test vector comprising a functional indicator gene can use a two cell system using filtered supernatants from the resistance test vector host cells to infect the target host cell. </p><p id="p0103" num="0103"> In certain embodiments, a particle-based resistance tests can be carried out with resistance test vectors derived from genomic viral vectors, e.g., pHIVAlucRHIN or pHIVAlucPOL, which can be cotransfected with the packaging expression vector pVL- env4070A (also referred to as pCXAS-4070Aenv). Alternatively, a particle-based resistance test may be carried out with resistance test vectors derived from subgenomic viral vectors which are cotransfected with the packaging expression vector pVL-env4070 and either PLTR-HIV3' or pCMV-HIV3'. In another embodiment of the invention, non-particle-based resistance tests can be carried out using each of the above described resistance test vectors by transfection of selected host cells in the absence of packaging expression vectors. </p><p id="p0104" num="0104"> In the case of the particle-based susceptibility and resistance test, resistance test vector viral particles can be produced by a first host cell (the resistance test vector host cell), 
<!-- EPO <DP n="33"/>-->
 that can be prepared by transfecting a packaging host cell with the resistance test vector and packaging expression vector(s) as described above. The resistance test vector viral particles can then be used to infect a second host cell (the target host cell) in which the expression of the indicator gene is measured. In a second type of particle-based susceptibility and resistance test, a single host cell type (the resistance test vector host cell) serves both purposes: some of the packaging host cells in a given culture can be transfected and produce resistance test vector viral particles and some of the host cells in the same culture can be the target of infection by the resistance test vector particles thus produced. Resistance tests employing a single host cell type are possible with resistance test vectors comprising a non-functional indicator gene with a permuted promoter since such indicator genes can be efficiently expressed upon infection of a permissive host cell, but are not efficiently expressed upon transfection of the same host cell type, and thus provide an opportunity to measure the effect of the anti-viral agent under evaluation. For similar reasons, resistance tests employing two cell types may be carried out by co-cultivating the two cell types as an alternative to infecting the second cell type with viral particles obtained from the supernatants of the first cell type. </p><p id="p0105" num="0105"> In the case of the non-particle-based susceptibility and resistance test, resistance tests can be performed by transfection of a single host cell with the resistance test vector in the absence of packaging expression vectors. Non-particle based resistance tests can be carried out using the resistance test vectors comprising non-functional indicator genes with either permuted promoters, permuted coding regions or inverted introns. These non-particle based resistance tests are performed by transfection of a single host cell type with each resistance test vector in the absence of packaging expression vectors. Although the non-functional indicator genes contained within these resistance test vectors are not efficiently expressed upon transfection of the host cells, there is detectable indicator gene expression resulting from non-viral particle-based reverse transcription. Reverse transcription and strand transfer results in the conversion of the permuted, non-functional indicator gene to a non-permuted, functional indicator gene. As reverse transcription is completely dependent upon the expression of the pol gene contained within each resistance test vector, anti-viral agents may be tested for their ability to inhibit the pol gene products, including, for example, reverse transcriptase, RNAse H, or integrase, encoded by the patient-derived segments contained within the resistance test vectors. As such, embodiments where the patient-derived segment comprises the entire pol gene are appropriate for this kind of assay. Reverse transcription and strand transfer results in the conversion of the non-functional indicator gene to a functional 
<!-- EPO <DP n="34"/>-->
 indicator gene. As reverse transcription depends upon the expression of the genes encoded by the patient-derived segment contained within each resistance test vector, anti-viral agents may be tested for their ability to inhibit the gene products encoded by the patient-derived segments contained within the resistance test vectors. </p><p id="p0106" num="0106"> The packaging host cells can be transfected with the resistance test vector and the appropriate packaging expression vector(s) to produce resistance test vector host cells. In certain embodiments, individual anti-viral agents, including integrase inhibitors such as raltegravir, elvitegravir (GS 9137 or JTK-303), GS-9224, MK-2048, L-870,810, L-870,812, L-731 ,988, L-900564, S/GSK-1349572, GSK-364735, BMS-707035, BMS-538203, S-1360, PF-04545030, 05177220, 05299617, 06259088, 06259089, 06259090, 06259091, 06259092, 06259093, and 06259094, as well as combinations thereof, can be added to individual plates of packaging host cells at the time of their transfection, at an appropriate range of concentrations. Twenty-four to 48 hours after transfection, target host cells can be infected by co-cultivation with resistance test vector host cells or with resistance test vector viral particles obtained from filtered supernatants of resistance test vector host cells. Each anti-viral agent, or combination thereof, can be added to the target host cells prior to or at the time of infection to achieve the same final concentration of the given agent, or agents, present during the transfection. In other embodiments, the anti-viral agent(s) can be omitted from the packaging host cell culture, and added only to the target host cells prior to or at the time of infection. </p><p id="p0107" num="0107"> Determination of the expression or inhibition of the indicator gene in the target host cells infected by co-cultivation or with filtered viral supernatants can be performed measuring indicator gene expression or activity. For example, in the case where the indicator gene is the firefly luc gene, luciferase activity can be measured. The reduction in luciferase activity observed for target host cells infected with a given preparation of resistance test vector viral particles in the presence of a given antiviral agent, or agents, as compared to a control run in the absence of the antiviral agent, generally relates to the log of the concentration of the antiviral agent as a sigmoidal curve. This inhibition curve can be used to calculate the apparent inhibitory concentration (IC) of that agent, or combination of agents, for the viral target product encoded by the patient-derived segments present in the resistance test vector. </p><p id="p0108" num="0108"> In the case of a one cell susceptibility and resistance test, host cells can be transfected with the resistance test vector and the appropriate packaging expression vector(s) to produce resistance test vector host cells. Individual antiviral agents, or combinations thereof, can be added to individual plates of transfected cells at the time of their transfection, at an 
<!-- EPO <DP n="35"/>-->
 appropriate range of concentrations. Twenty-four to 72 hours after transfection, cells can be collected and assayed for indicator gene, e.g. , firefly luciferase, activity. As transfected cells in the culture do not efficiently express the indicator gene, transfected cells in the culture, as well superinfected cells in the culture, can serve as target host cells for indicator gene expression. The reduction in luciferase activity observed for cells transfected in the presence of a given antiviral agent, or agents as compared to a control run in the absence of the antiviral agent(s), generally relates to the log of the concentration of the antiviral agent as a sigmoidal curve. This inhibition curve can be used to calculate the apparent inhibitory concentration (IC) of an agent, or combination of agents, for the viral target product encoded by the patient-derived segments present in the resistance test vector. </p><p id="p0109" num="0109"> Antiviral Drugs/Drug Candidates </p><p id="p0110" num="0110"> The antiviral drugs being added to the test system can be added at selected times depending upon the target of the antiviral drug. HIV integrase inhibitors, including raltegravir, elvitegravir (GS 9137 or JTK-303), GS-9224, MK-2048, L-870,810, L-870,812, L-731 ,988, L-900564, S/GSK-1349572, GSK-364735, BMS-707035, BMS-538203, S-1360, PF-04545030, 05177220, 05299617, 06259088, 06259089, 06259090, 06259091 , 06259092, 06259093, and 06259094, as well as combinations thereof, can be added to individual plates of target host cells at the time of infection by the resistance test vector viral particles, at a test concentration. Alternatively, the antiviral drugs may be present throughout the assay. The test concentration is selected from a range of concentrations which is typically between about 0.1 nM and about 100 μΜ, between about 1 nM and about 100 μΜ, between about 10 nM and about 100 μΜ, between about 0.1 nM and about 10 μΜ, between about 1 nM and about 10 μΜ, between about 10 nM and about 100 μΜ, between about 0.1 nM and about 1 μΜ, between about 1 nM and about 1 μΜ, or between about 0.01 nM and about 0.1 μΜ. </p><p id="p0111" num="0111"> Further guidance on integrase inhibitors that can be used in the methods of the invention may be found in, for example, Tramontano et al , 2005, Antiviral Res. 65:1 17-24; Andreola, 2004, Curr Pharm Des 10:3713-23; Hang et al , 2004, Biochem Biophys Res Commun 317:321-9; Skillman et al , 2002, Bioorg Chem 30:443-58; Dayam et al , 2005, J Med Chem. 48:1 1 1-20; Turpin, 2003, Expert Rev Anti Infect Ther 1 :97-128; Sechi et al , 2004, J Med Chem 47:5298-310; Middleton et al, 2004, Antiviral Res 64:35-45; Boyle, 2004, AIDS Read 14:412-6, 452; Witvrouw et al , 2004, Curr Drug Metab. 5:291-304; Reinke et al , 2004, Virology 326:203-19; and Johnson et al, 2004, Curr Top Med Chem 4: 1059-77; each of which is incorporated by reference in its entirety. 
<!-- EPO <DP n="36"/>-->
 In certain embodiments, a candidate antiviral compound can be tested in a drug susceptibility test of the invention. The candidate antiviral compound can be added to the test system at an appropriate concentration and at selected times depending upon the protein target of the candidate anti-viral. Alternatively, more than one candidate antiviral compound may be tested or a candidate antiviral compound may be tested in combination with an approved antiviral drug such as AZT, ddl, ddC, d4T, 3TC, saquinavir, ritonavir, indinavir, and the like, or a compound which is undergoing clinical trials. The effectiveness of the candidate antiviral compound can be evaluated by measuring the activity of the indicator gene. If the candidate compound is effective at inhibiting a viral polypeptide activity, the activity of the indicator gene will be reduced in the presence of the candidate compound relative to the activity observed in the absence of the candidate compound. In another aspect of this embodiment, the drug susceptibility and resistance test may be used to screen for viral mutants. Following the identification of resistant mutants to either known anti-viral drugs or candidate anti-viral drugs the resistant mutants can be isolated and the DNA analyzed. A library of viral resistant mutants can thus be assembled enabling the screening of candidate anti-viral agents, either alone or in combination with other known or putative anti-viral agents. </p><p id="p0112" num="0112">Methods of Determining Replication Capacity of an HIV </p><p id="p0113" num="0113"> In another aspect, the invention provides a method for determining the replication capacity of a human immunodeficiency virus (HIV). In certain embodiments, methods are provided for determining the replication capacity of a human immunodeficiency virus (HIV), comprising the steps of detecting in a biological sample from a patient infected with HIV a nucleic acid encoding an HIV integrase that comprises a mutation at codon 143, wherein the mutation at codon 143 does not encode arginine (R) or cysteine (C), and a mutation at codon 97, wherein the presence of the integrase-encoding nucleic acid in the biological sample indicates that the patient's HIV has a decreased replication capacity relative to a reference HIV, thereby assessing viral replication capacity. In certain embodiments, the mutation at codon 143 encodes an amino acid selected from the group consisting of histidine (H), glycine (G), and serine (S), and the mutation at codon 97 is an alanine (A) residue. </p><p id="p0114" num="0114"> In certain embodiments, the methods for determining replication capacity comprise culturing a host cell comprising a patient-derived segment and an indicator gene, measuring the activity of the indicator gene in the host cell, wherein the activity of the indicator gene 
<!-- EPO <DP n="37"/>-->
 between the activity of the indicator gene measured in step (b) relative to a reference activity indicates the replication capacity of the HIV, thereby determining the replication capacity of the HIV. In certain embodiments, the activity of the indicator gene depends on the activity of a polypeptide encoded by the patient-derived segment. In certain embodiments, the patient- derived segment comprises a nucleic acid sequence that encodes integrase. </p><p id="p0115" num="0115"> In certain embodiments, the reference activity of the indicator gene is an amount of activity determined by performing a method of the invention with a standard laboratory viral segment. In certain embodiments, the standard laboratory viral segment comprises a nucleic acid sequence from HIV strain NL4-3. In certain embodiments, the standard laboratory viral segment comprises a nucleic acid sequence from HIV strain IIIB. </p><p id="p0116" num="0116"> In certain embodiments, the HIV is determined to have increased replication capacity relative to the reference. In certain embodiments, the HIV is determined to have reduced replication capacity relative to the reference. In certain embodiments, the host cell is a 293 cell. In certain embodiments, the patient-derived segment encodes integrase. </p><p id="p0117" num="0117"> In certain embodiments, the phenotypic analysis can be performed using recombinant virus assays ("RVAs"). In certain embodiments, RVAs use virus stocks generated by homologous recombination or between viral vectors and viral gene sequences, amplified from the patient virus. In certain embodiments, RVAs virus stocks generated by ligating viral gene sequences, amplified from patient virus, into viral vectors. In certain embodiments, the viral vector is a HIV vector and the viral gene sequences comprise pol sequences, or a portion thereof. In certain embodiments, the viral gene sequences encode reverse transcriptase. In certain embodiments, the viral gene sequences encode integrase. In certain embodiments, the viral gene sequences encode the RNAse H portion of reverse transcriptase. In certain embodiments, the viral gene sequences encode reverse transcriptase and integrase. In certain embodiments, the viral gene sequences encode the RNAse H portion of reverse transcriptase and integrase. </p><p id="p0118" num="0118"> The methods of determining replication capacity can be used, for example, with nucleic acids from amplified viral gene sequences. As discussed below, the nucleic acid can be amplified from any sample known by one of skill in the art to contain a viral gene sequence, without limitation. For example, the sample can be a sample from a human or an animal infected with the virus or a sample from a culture of viral cells. In certain embodiments, the viral sample comprises a genetically modified laboratory strain. In certain embodiments, the genetically modified laboratory strain comprises a site-directed mutation. 
<!-- EPO <DP n="38"/>-->
 In other embodiments, the viral sample comprises a wild-type isolate. In certain embodiments, the wild-type isolate is obtained from a treatment-naive patient. In certain embodiments, the wild-type isolate is obtained from a treatment-experienced patient. </p><p id="p0119" num="0119"> A resistance test vector ("RTV") can then be constructed by incorporating the amplified viral gene sequences into a replication defective viral vector by using any method known in the art of incorporating gene sequences into a vector. In one embodiment, restrictions enzymes and conventional cloning methods are used. See Sambrook et al , 2001, Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory, 3.sup.rd ed., NY; and Ausubel et al , 1989, Current Protocols in Molecular Biology, Greene Publishing Associates and Wiley Interscience, NY. In a preferred embodiment, Apal, PinAI, and Xhol restriction enzymes are used. Preferably, the replication defective viral vector is the indicator gene viral vector ("IGVV"). In a preferred embodiment, the viral vector contains a means for detecting replication of the RTV. Preferably, the viral vector comprises a luciferase gene. </p><p id="p0120" num="0120"> The assay can be performed by first co-transfecting host cells with RTV DNA and a plasmid that expresses the envelope proteins of another retrovirus, for example, amphotropic murine leukemia virus (MLV). Following transfection, viral particles can be harvested from the cell culture and used to infect fresh target cells in the presence of varying amounts of antiviral drug(s). The completion of a single round of viral replication in the fresh target cells can be detected by the means for detecting replication contained in the vector. In a preferred embodiment, the means for detecting replication is an indicator gene. In a preferred embodiment, the indicator gene is firefly luciferase. In such preferred embodiments, the completion of a single round of viral replication results in the production of luciferase. </p><p id="p0121" num="0121"> In certain embodiments, the HIV strain that is evaluated is a wild-type isolate of HIV. In other embodiments, the HIV strain that is evaluated is a mutant strain of HIV. In certain embodiments, such mutants can be isolated from patients. In other embodiments, the mutants can be constructed by site-directed mutagenesis or other equivalent techniques known to one of skill in the art. In still other embodiments, the mutants can be isolated from cell culture. The cultures can comprise multiple passages through cell culture in the presence of antiviral compounds to select for mutations that accumulate in culture in the presence of such compounds. In certain embodiments, the antiviral compounds can be L-870,810 or L- 731 ,988. </p><p id="p0122" num="0122"> In one embodiment, viral nucleic acid, for example, HIV-1 RNA is extracted from plasma samples, and a fragment of, or entire viral genes can be amplified by methods such as, 
<!-- EPO <DP n="39"/>-->
 but not limited to PCR. See, e.g. , Hertogs et al, 1998, Antimicrob. Agents Chemother. 42(2):269-76. In one example, a 1.8-kb fragment containing the portion of HIV RT corresponding to RNAse H and integrase coding sequence can be amplified by reverse transcription-PCR. In another example, a 3.3-kb fragment containing the entire RT and integrase coding sequence can be amplified by reverse transcription-PCR. The pool of amplified nucleic acid, for example, the RH-IN-coding sequences, can then be cotransfected into a host cell such as CD4<sup>+</sup> T lymphocytes (MT4) with the a plasmid from which most of the RH-IN sequences are deleted. Homologous recombination can then lead to the generation of chimeric viruses containing viral coding sequences, such as the RH- and IN-coding sequences derived from HIV RNA in plasma. The replication capacities of the chimeric viruses can be determined by any cell viability assay known in the art, and compared to replication capacities of a reference to assess whether a virus has altered replication capacity or is resistant or hypersusceptible to the antiviral drug. In certain embodiments, the reference can be the replication capacities of a statistically significant number of individual viral isolates. In other embodiments, the reference can be the replication capacity of a reference virus such as NL4-3 or IIIB. For example, an MT4 cell-3-(4,5-dimethylthiazol-2-yl)-2,5- diphenyltetrazolium bromide-based cell viability assay can be used in an automated system that allows high sample throughput. </p><p id="p0123" num="0123"> Other assays for evaluating the phenotypic susceptibility of a virus to anti-viral drugs known to one of skill in the art can be adapted to determine replication capacity or to determine antiviral drug susceptibility or resistance. See, e.g., Shi and Mellors, 1997, Antimicrob Agents Chemother. 41(12):2781-85; Gervaix et al, 1997, Proc Natl Acad Sci U.S.A. 94(9):4653-8; Race et al, 1999, AIDS 13:2061-2068, incorporated herein by reference in their entireties, according to the method of the present invention. </p><p id="p0124" num="0124"> One skilled in the art will recognize that the above-described methods for determining the replication capacity of an HIV can readily be adapted to perform methods for determining raltegravir or elvitegravir susceptibility. Similarly, one of skill in the art will recognize that the above-described methods for determining raltegravir or elvitegravir susceptibility can readily be adapted to perform methods for determining the replication capacity of an HIV. Adaptation of the methods for determining replication capacity can generally comprise performing the methods of the invention in the presence of varying concentration of antiviral drug. By doing so, the susceptibility of the HIV to raltegravir or elvitegravir can be determined. Similarly, performing a method for determining raltegravir or elvitegravir 
<!-- EPO <DP n="40"/>-->
 susceptibility in the absence of any antiviral drug can provide a measure of the replication capacity of the HIV used in the method. </p><p id="p0125" num="0125">Detecting the Presence or Absence of Mutations in a Virus </p><p id="p0126" num="0126"> The presence or absence of a mutation in a virus can be determined by any means known in the art for detecting a mutation. The mutation can be detected in the viral gene that encodes a particular protein, or in the protein itself, i.e., in the amino acid sequence of the protein. </p><p id="p0127" num="0127"> In one embodiment, the mutation is in the viral genome. Such a mutation can be in, for example, a gene encoding a viral protein, in a genetic element such as a cis or tra acting regulatory sequence of a gene encoding a viral protein, an intergenic sequence, or an intron sequence. The mutation can affect any aspect of the structure, function, replication or environment of the virus that changes its susceptibility to an anti-viral treatment and/or its replication capacity. In one embodiment, the mutation is in a gene encoding a viral protein that is the target of an currently available anti-viral treatment. In other embodiments, the mutation is in a gene or other genetic element that is not the target of a currently-available anti-viral treatment. </p><p id="p0128" num="0128"> A mutation within a viral gene can be detected by utilizing any suitable technique known to one of skill in the art without limitation. Viral DNA or RNA can be used as the starting point for such assay techniques, and may be isolated according to standard procedures which are well known to those of skill in the art. </p><p id="p0129" num="0129"> The detection of a mutation in specific nucleic acid sequences, such as in a particular region of a viral gene, can be accomplished by a variety of methods including, but not limited to, restriction-fragment-length-polymorphism detection based on allele-specific restriction- endonuclease cleavage (Kan and Dozy, 1978, Lancet ii:910-912), mismatch-repair detection (Faham and Cox, 1995, Genome Res 5:474-482), binding of utS protein (Wagner et al, 1995, Nucl Acids Res 23:3944-3948), denaturing-gradient gel electrophoresis (Fisher et al, 1983, Proc. Natl. Acad. Sci. U.S.A. 80: 1579-83), single-strand-conformation-polymorphism detection (Orita et al, 1983, Genomics 5:874-879), RNAase cleavage at mismatched base- pairs (Myers et al , 1985, Science 230: 1242), chemical (Cotton et al , 1988, Proc. Natl. Acad. Sci. U.S.A. 85:4397-4401 ) or enzymatic (Youil et al , 1995, Proc. Natl. Acad. Sci. U.S.A. 92:87-91) cleavage of heteroduplex DNA, methods based on oligonucleotide-specific primer extension (Syvanen et al, 1990, Genomics 8:684-692), genetic bit analysis (Nikiforov et al, 
<!-- EPO <DP n="41"/>-->
 1994, Nucl Acids Res 22:4167-4175), oligonucleotide-ligation assay (Landegren et al , 1988, Science 241 : 1077), oligonucleotide-specific ligation chain reaction ("LCR") (Barrany, 1991 , Proc. Natl. Acad. Sci. U.S.A. 88: 189-193), gap-LCR (Abravaya et al , 1995, Nucl Acids Res 23:675-682), radioactive or fluorescent DNA sequencing using standard procedures well known in the art, and peptide nucleic acid (PNA) assays (Oram et al , 1993, Nucl. Acids Res. 21 :5332-5356; Thiede et al , 1996, Nucl. Acids Res. 24:983-984). </p><p id="p0130" num="0130"> In addition, viral DNA or RNA may be used in hybridization or amplification assays to detect abnormalities involving gene structure, including point mutations, insertions, deletions and genomic rearrangements. Such assays may include, but are not limited to, Southern analyses (Southern, 1975, J. Mol. Biol. 98:503-517), single stranded conformational polymorphism analyses (SSCP) (Orita et al , 1989, Proc. Natl. Acad. Sci. USA 86:2766- 2770), and PCR analyses (U.S. Pat. Nos. 4,683,202; 4,683,195; 4,800,159; and 4,965,188; PCR Strategies, 1995 Innis et al. (eds.), Academic Press, Inc.). </p><p id="p0131" num="0131"> Such diagnostic methods for the detection of a gene-specific mutation can involve for example, contacting and incubating the viral nucleic acids with one or more labeled nucleic acid reagents including recombinant DNA molecules, cloned genes or degenerate variants thereof, under conditions favorable for the specific annealing of these reagents to their complementary sequences. Preferably, the lengths of these nucleic acid reagents are at least 15 to 30 nucleotides. After incubation, all non-annealed nucleic acids are removed from the nucleic acid molecule hybrid. The presence of nucleic acids which have hybridized, if any such molecules exist, is then detected. Using such a detection scheme, the nucleic acid from the virus can be immobilized, for example, to a solid support such as a membrane, or a plastic surface such as that on a microtiter plate or polystyrene beads. In this case, after incubation, non-annealed, labeled nucleic acid reagents of the type described above are easily removed. Detection of the remaining, annealed, labeled nucleic acid reagents is accomplished using standard techniques well-known to those in the art. The gene sequences to which the nucleic acid reagents have annealed can be compared to the annealing pattern expected from a normal gene sequence in order to determine whether a gene mutation is present. </p><p id="p0132" num="0132"> These techniques can easily be adapted to provide high-throughput methods for detecting mutations in viral genomes. For example, a gene array from Affymetrix (Affymetrix, Inc., Sunnyvale, Calif.) can be used to rapidly identify genotypes of a large number of individual viruses. Affymetrix gene arrays, and methods of making and using such arrays, are described in, for example, U.S. Pat. Nos. 6,551 ,784, 6,548,257, 6,505,125, 
<!-- EPO <DP n="42"/>-->
 6,489,1 14, 6,451 ,536, 6,410,229, 6,391 ,550, 6,379,895, 6,355,432, 6,342,355, 6,333,155, 6,308,170, 6,291,183, 6,287,850, 6,261,776, 6,225,625, 6,197,506, 6,168,948, 6,156,501, 6,141 ,096, 6,040,138, 6,022,963, 5,919,523, 5,837,832, 5,744,305, 5,834,758, and 5,631,734, each of which is hereby incorporated by reference in its entirety. </p><p id="p0133" num="0133"> In addition, Ausubel et al, eds., Current Protocols in Molecular Biology, 2002, Vol. 4, Unit 25B, Ch. 22, which is hereby incorporated by reference in its entirety, provides further guidance on construction and use of a gene array for determining the genotypes of a large number of viral isolates. Finally, U.S. Pat. Nos. 6,670,124; 6,617,1 12; 6,309,823; 6,284,465; and 5,723,320, each of which is incorporated by reference in its entirety, describe related array technologies that can readily be adapted for rapid identification of a large number of viral genotypes by one of skill in the art. </p><p id="p0134" num="0134"> Alternative diagnostic methods for the detection of gene specific nucleic acid molecules may involve their amplification, e.g., by PCR (U.S. Pat. Nos. 4,683,202; 4,683,195; 4,800,159; and 4,965,188; PCR Strategies, 1995 Innis et al. (eds.), Academic Press, Inc.), followed by the detection of the amplified molecules using techniques well known to those of skill in the art. The resulting amplified sequences can be compared to those which would be expected if the nucleic acid being amplified contained only normal copies of the respective gene in order to determine whether a gene mutation exists. </p><p id="p0135" num="0135"> Additionally, the nucleic acid can be sequenced by any sequencing method known in the art. For example, the viral DNA can be sequenced by the dideoxy method of Sanger et al, 1977, PNAS USA 74:5463, as further described by Messing et al, 1981 , Nuc. Acids Res. 9:309, or by the method of Maxam et al , 1980, Methods in Enzymology 65:499. See also the techniques described in Sambrook et al, 2001 , Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory, 3.sup.rd ed., NY; and Ausubel et al , 1989, Current Protocols in Molecular Biology, Greene Publishing Associates and Wiley Interscience, NY. </p><p id="p0136" num="0136"> Antibodies directed against the viral gene products, i.e. , viral proteins or viral peptide fragments can also be used to detect mutations in the viral proteins. Alternatively, the viral protein or peptide fragments of interest can be sequenced by any sequencing method known in the art in order to yield the amino acid sequence of the protein of interest. An example of such a method is the Edman degradation method which can be used to sequence small proteins or polypeptides. Larger proteins can be initially cleaved by chemical or enzymatic reagents known in the art, for example, cyanogen bromide, hydroxylamine, trypsin or chymotrypsin, and then sequenced by the Edman degradation method. 
<!-- EPO <DP n="43"/>-->
 Computer-Implemented Methods for Determining Integrase Inhibitor Susceptibility or Replication Capacity </p><p id="p0137" num="0137"> In another aspect, the present invention provides computer-implemented methods for determining the susceptibility of an HIV to an integrase inhibitor (e.g., raltegravir or elvitegravir) or determining the replication capacity of an HIV. In such embodiments, the methods of the invention are adapted to take advantage of the processing power of modern computers. One of skill in the art can readily adapt the methods in such a manner. </p><p id="p0138" num="0138"> In certain embodiments, the invention provides a computer-implemented method for determining the susceptibility of an HIV to the integrase inhibitor. In certain embodiments, the method comprises inputting information regarding the activity of an indicator gene determined according to a method of the invention and a reference activity of an indicator gene and instructions to compare the activity of the indicator gene determined according to a method of the invention with the reference activity of the indicator gene into a computer memory; and comparing the activity of the indicator gene determined according to a method of the invention with the reference activity of the indicator gene in the computer memory, wherein the difference between the measured activity of the indicator gene relative to the reference activity correlates with the susceptibility of the HIV to the integrase inhibitor, thereby determining the susceptibility of the HIV to the integrase inhibitor. </p><p id="p0139" num="0139"> In certain embodiments, the methods further comprise displaying the susceptibility of the HIV to the integrase inhibitor on a display of the computer. In certain embodiments, the methods further comprise printing the susceptibility of the HIV to the integrase inhibitor on a paper. </p><p id="p0140" num="0140"> In another aspect, the invention provides a print-out indicating the susceptibility of the HIV to the integrase inhibitor determined according to a method of the invention. In still another aspect, the invention provides a computer-readable medium comprising data indicating the susceptibility of the HIV to the integrase inhibitor determined according to a method of the invention. </p><p id="p0141" num="0141"> In another aspect, the invention provides a computer-implemented method for determining the replication capacity of an HIV. In certain embodiments, the method comprises inputting information regarding the activity of an indicator gene determined according to a method of the invention and a reference activity of an indicator gene and instructions to compare the activity of the indicator gene determined according to a method of the invention with the reference activity of the indicator gene into a computer memory; and 
<!-- EPO <DP n="44"/>-->
 comparing the activity of the indicator gene determined according to a method of the invention with the reference activity of the indicator gene in the computer memory, wherein the comparison of the measured activity of the indicator gene relative to the reference activity indicates the replication capacity of the HIV, thereby determining the replication capacity of the HIV. </p><p id="p0142" num="0142"> In certain embodiments, the methods further comprise displaying the replication capacity of the HIV on a display of the computer. In certain embodiments, the methods further comprise printing the replication capacity of the HIV on a paper. </p><p id="p0143" num="0143"> In another aspect, the invention provides a print-out indicating the replication capacity of the HIV, where the replication capacity is determined according to a method of the invention. In still another aspect, the invention provides a computer-readable medium comprising data indicating the replication capacity of the HIV, where the replication capacity is determined according to a method of the invention. </p><p id="p0144" num="0144"> In still another aspect, the invention provides an article of manufacture that comprises computer-readable instructions for performing a method of the invention. </p><p id="p0145" num="0145"> In yet another aspect, the invention provides a computer system that is configured to perform a method of the invention. </p><p id="p0146" num="0146">Methods for Determining the Selective Advantage of an Integrase Mutation or Mutation Profile </p><p id="p0147" num="0147"> In other aspects, methods for determining the selective advantage of an integrase mutation or mutation profile are provided. These methods comprise the steps of determining the number of nucleotide substitutions in an integrase-encoding nucleic acid at codon 143 that are required to convert the codon encoding tyrosine to a codon encoding arginine, cysteine, histidine, glycine, or serine; determining the reduction in susceptibility to an integrase inhibitor that is conferred by the amino acid substitution at position 143; determining the impact of amino acid substitutions at position 143 on replication capacity; determining the number of secondary mutations and their impact on susceptibility to the integrase inhibitor, replication capacity, or both susceptibility and replication capacity; and determining the selective advantage of the mutation or the mutation profile, wherein the fewer the number of nucleotide substitutions required for the amino acid substitution, the higher the reduction of the susceptibility to the integrase inhibitor, the lower the impact on replication capacity, and the fewer the number of secondary mutations required to achieve the 
<!-- EPO <DP n="45"/>-->
 reduction in susceptibility to the integrase inhibitor, the greater the selective advantage for the mutation or mutation profile, thereby determining the selective advantage for the mutation or mutation profile. In some embodiments, the integrase inhibitor is raltegravir or elvitegravir. Viruses and Viral Samples </p><p id="p0148" num="0148"> Any HIV known by one of skill in the art without limitation can be used as a source of patient-derived segments or viral sequences for use in the methods of the invention. In one embodiment of the invention, the virus is human immunodeficiency virus type 1 ("HIV-1"). In certain embodiments, the virus is human immunodeficiency virus type 2 ("HIV -2"). In other embodiments, the virus is a lentivirus, e.g. simian or feline immunodeficiency virus (SIV, FIV). </p><p id="p0149" num="0149"> Viruses from which patient-derived segments or viral gene sequences are obtained can be found in a viral sample obtained by any means known in the art for obtaining viral samples. Such methods include, but are not limited to, obtaining a viral sample from an individual infected with the virus or obtaining a viral sample from a viral culture. In one embodiment, the viral sample is obtained from a human individual infected with the virus. The viral sample could be obtained from any part of the infected individual's body or any secretion expected to contain the virus. Examples of such parts include, but are not limited to blood, serum, plasma, sputum, lymphatic fluid, semen, vaginal mucus and samples of other bodily fluids. In a preferred embodiment, the sample is a blood, serum or plasma sample. </p><p id="p0150" num="0150"> In another embodiment, a patient-derived segment or viral gene sequence can be obtained from a virus that can be obtained from a culture. In some embodiments, the culture can be obtained from a laboratory. In other embodiments, the culture can be obtained from a collection, for example, the American Type Culture Collection. </p><p id="p0151" num="0151"> In another embodiment, a patient-derived segment or viral gene sequence can be obtained from a genetically modified virus. The virus can be genetically modified using any method known in the art for genetically modifying a virus. For example, the virus can be grown for a desired number of generations in a laboratory culture. In one embodiment, no selective pressure is applied (i.e. , the virus is not subjected to a treatment that favors the replication of viruses with certain characteristics), and new mutations accumulate through random genetic drift. In another embodiment, a selective pressure is applied to the virus as it is grown in culture (i. e. , the virus is grown under conditions that favor the replication of 
<!-- EPO <DP n="46"/>-->
 viruses having one or more characteristics). In one embodiment, the selective pressure is an anti-viral treatment. Any known anti-viral treatment can be used as the selective pressure. </p><p id="p0152" num="0152"> In another aspect, the patient-derived segment or viral gene sequence can be made by mutagenizing a virus, a viral genome, or a part of a viral genome. Any method of mutagenesis known in the art can be used for this purpose. In certain embodiments, the mutagenesis is essentially random. In certain embodiments, the essentially random mutagenesis is performed by exposing the virus, viral genome or part of the viral genome to a mutagenic treatment. In another embodiment, a gene that encodes a viral protein that is the target of an anti -viral therapy is mutagenized. Examples of essentially random mutagenic treatments include, for example, exposure to mutagenic substances (e.g. , ethidium bromide, ethylmethanesulphonate, ethyl nitroso urea (ENU) etc.) radiation (e.g. , ultraviolet light), the insertion and/or removal of transposable elements (e.g., Tn5, TnlO), or replication in a cell, cell extract, or in vitro replication system that has an increased rate of mutagenesis. See, e.g., Russell et al , 1979, Proc. Nat. Acad. Sci. USA 76:5918-5922; Russell, W., 1982, Environmental Mutagens and Carcinogens: Proceedings of the Third International Conference on Environmental Mutagens. One of skill in the art will appreciate that while each of these methods of mutagenesis is essentially random, at a molecular level, each has its own preferred targets. </p><p id="p0153" num="0153"> In another aspect, the patient-derived segment or viral gene sequence can be made using site-directed mutagenesis. Any method of site-directed mutagenesis known in the art can be used (see e.g. , Sambrook et al , 2001 , Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory, S.sup.rd ed., NY; and Ausubel et al, 2005, Current Protocols in Molecular Biology, Greene Publishing Associates and Wiley Interscience, NY, and Sarkar and Sommer, 1990, Biotechniques, 8:404-407). The site directed mutagenesis can be directed to, e.g., a particular gene or genomic region, a particular part of a gene or genomic region, or one or a few particular nucleotides within a gene or genomic region. In one embodiment, the site directed mutagenesis is directed to a viral genomic region, gene, gene fragment, or nucleotide based on one or more criteria. In one embodiment, a gene or a portion of a gene is subjected to site-directed mutagenesis because it encodes a protein that is known or suspected to be a target of an anti-viral therapy, e.g., the pol gene encoding HIV integrase, or a portion thereof. In another embodiment, a portion of a gene, or one or a few nucleotides within a gene, are selected for site-directed mutagenesis. In one embodiment, the nucleotides to be mutagenized encode amino acid residues that are known or suspected to interact with an anti- 
<!-- EPO <DP n="47"/>-->
 viral compound. In another embodiment, the nucleotides to be mutagenized encode amino acid residues that are known or suspected to be mutated in viral strains that are resistant or susceptible or hypersusceptible to one or more antiviral agents. In another embodiment, the mutagenized nucleotides encode amino acid residues that are adjacent to or near in the primary sequence of the protein residues known or suspected to interact with an anti-viral compound or known or suspected to be mutated in viral strains that are resistant or susceptible or hypersusceptible to one or more antiviral agents. In another embodiment, the mutagenized nucleotides encode amino acid residues that are adjacent to or near to in the secondary, tertiary or quaternary structure of the protein residues known or suspected to interact with an anti-viral compound or known or suspected to be mutated in viral strains having an altered replication capacity. In another embodiment, the mutagenized nucleotides encode amino acid residues in or near the active site of a protein that is known or suspected to bind to an anti-viral compound. </p><p id="p0154" num="0154"> EXAMPLES</p><p id="p0155" num="0155">EXAMPLE 1 </p><p id="p0156" num="0156">Identification of Primary Mutations in Integrase </p><p id="p0157" num="0157"> Mutations Y143R and Y143C of HIV-1 integrase define a major mutational pathway for resistance to raltegravir. Other amino acid substitutions at position 143 are uncommon, and their effects on raltegravir or elvitegravir susceptibility are not well characterized. Here, alternative amino acid substitutions at position 143 in clinical isolates were identified, and their ability to confer reduced susceptibility to raltegravir and elvitegravir was demonstrated. In addition, the impact of secondary mutations on susceptibility to raltegravir and elvitegravir was analyzed. </p><p id="p0158" num="0158"> One hundred sixteen clinical HIV isolates containing amino acid substitutions at position 143 were analyzed. Based on nucleotide sequence, viruses were identified that encoded amino acid substitutions at integrase position 143. The substitutions included novel mutations Y143D, Y143H, Y143G, and Y143S, in addition to the well-recognized mutations Y143R and Y143C (Fig. 1 ). Figure 1 is a table showing the amino acid substitutions identified at position 143 of integrase in each of the one hundred sixteen virus samples. The majority of samples (n=76) had a single amino acid substitution present at position 143 and did not have an amino acid substitution at position 148 or 155. These are listed in the top panel of the table. The number of population samples that had two or more amino acid substitution present at position 143 and that did not have an amino acid substitution at 
<!-- EPO <DP n="48"/>-->
 position 148 or 155 (n=17) are listed in the second panel. The number of population samples that had at least a single amino acid substitution present at position 143 and that also had an amino acid substitution at position 155 (n=18) are listed in the thrid panel. The number of population samples that had at least a single amino acid substitution present at position 143 and that also had an amino acid substitution at position 148 (n=5) are listed in the bottom panel. </p><p id="p0159" num="0159"> Clonal analysis was conducted on twenty viral populations (Fig. 2). Forty to forty- eight clones from each virus population were included in this analysis. The samples indicated with an asterisk contain mixtures of Y 143 mutation clones and N155H clones or Q148H clones. </p><p id="p0160" num="0160"> Figure 3 is a schematic diagram showing codon usage for different amino acid substitutions at position 143 of integrase. Two wild-type codons, TAC and TAT, coding for tyrosine (Y) are shown in the top hexagons. Transition from wild type amino acid tyrosine (Y) to substitutions Y143C/H/S requires one nucleotide change, but two nucleotide changes are needed for Y143G/R. Both Y143S and Y143G also require transversion mutations (underlined). </p><p id="p0161" num="0161">EXAMPLE 2 </p><p id="p0162" num="0162">Analysis of Viral Susceptibility to Raltegravir </p><p id="p0163" num="0163"> This example provides methods and compositions for accurately and reproducibly measuring the susceptibility of HIV infecting a patient to raltegravir. The methods described in this example can also be used to determine susceptibility of HIV infecting a patient to elvitegravir or other inhibitors of HIV integrase activity, or to determine the replication capacity of the HIV. The drug susceptibility tests described herein are a modification of the methods for phenotypic drug susceptibility and resistance tests described in U.S. Pat. No. 5,837,464 (International Publication Number WO 97/27319) which is hereby incorporated by reference in its entirety. </p><p id="p0164" num="0164"> Construction of Resistance Test Vector Libraries </p><p id="p0165" num="0165"> Patient-derived segment(s) corresponding to either the entire pol gene, encoding HIV protease, reverse transcriptase, and integrase(hereinafter "POL"), or the portion of pol encoding amino acids 319-440 of reverse transcriptase, the RNAse H domain of reverse transcriptase and integrase (hereinafter "RHIN"), were amplified by the reverse transcription- polymerase chain reaction method (RT-PCR) using viral RNA isolated from viral particles 
<!-- EPO <DP n="49"/>-->
 present in the plasma or serum of HIV-infected individuals as follows. Virus was pelleted by centrifugation at 20,400xg for 60 minutes from plasma (typically, 1 ml) prepared from blood samples collected in evacuated tubes containing either EDTA, acid-citrate dextrose, or heparin as an anticoagulant. Virus particles were disrupted by resuspending the pellets in 200 μΐ of lysis buffer (4 M guanidine thiocyanate, 0.1 M Tris HC1 [pH 8.0], 0.5% sodium lauryl sarcosine, 1% dithiothreitol). RNA was extracted from viral lysates by using oligo(dT) linked to magnetic beads (Dynal, Oslo, Norway). Reverse transcription was performed with Superscript III (Invitrogen) at 50 degrees. </p><p id="p0166" num="0166"> From the resultant cDNA, either POL or RHIN sequences were amplified using the Advantage High Fidelity PCR kit (BD Biosciences; Clontech). A retroviral vector designed to measure antiretroviral drug susceptibility was constructed by using an infectious molecular clone of HIV-1. The vector, referred to herein as an indicator gene viral vector (IGVV), is replication defective and contains a luciferase expression cassette inserted within a deleted region of the envelope (env) gene. The IGVV is described in U.S. Pat. No. 5,837,464 (International Publication Number WO 97/27319) which is hereby incorporated by reference in its entirety. This retroviral vector was further modified to allow insertion of either the entire pol gene (POL) or the portion of pol encoding amino acids 319-440 of reverse transcriptase, the RNase H domain of reverse transcriptase, and integrase (RHIN) by engineering an Xhol restriction enzyme recognition site into vif. Prior to doing this, an Xho 1 site in nef was deleted. Resistance test vectors (RTVs) were constructed by incorporating amplified POL or RHIN into the IGVV by using Apal and Xhol or PinAI and Xhol restriction sites respectively. RTVs were prepared as libraries (pools) in order to capture and preserve the pol or RHIN sequence heterogeneity of the virus in the patient. POL amplification products were digested with Apal and Xhol , purified by agarose gel electrophoresis, and ligated to Apal- and Xho 1 -digested IGVV DNA. RHIN amplification products were digested with PinAI and Xhol , purified by agarose gel electrophoresis, and ligated to PinAI and Xhol -digested IGVV DNA. Ligation reactions were used to transform competent Escherichia coli (Invitrogen, Carlsbad, Calif.). An aliquot of each transformation was plated onto agar, and colony counts were used to estimate the number of patient-derived segments represented in each RTV library. RTV libraries that comprised less than 50 members are not considered representative of the patient virus. </p><p id="p0167" num="0167"> A packaging expression vector encoding an amphotrophic MuLV 4070A env gene product (described in U.S. Pat. No. 5,837,464) enables production in a host cell of viral 
<!-- EPO <DP n="50"/>-->
 particles which can efficiently infect human target cells. RTV libraries encoding all HIV genes with the exception of env, produced as described above, were used to transfect a packaging host cell. The packaging expression vector which encodes the amphotrophic MuLV 4070A env gene product is used with the resistance test vector to enable production of infectious pseudotyped viral particles comprising the resistance test vector libraries. </p><p id="p0168" num="0168"> Anti-HIV Drug Susceptibility Assays </p><p id="p0169" num="0169"> Raltegravir susceptibility tests performed with resistance test vectors were carried out using packaging host and target host cells consisting of the human embryonic kidney cell line 293. Susceptibility tests were carried out with the RTV libraries by using viral particles comprising the RTV libraries to infect a host cell in which the expression of the indicator gene is measured. The amount of indicator gene (luciferase) activity detected in infected cells is used as a direct measure of "infectivity," i.e. , the ability of the virus to complete a single round of replication. Thus, drug susceptibility can be determined by plotting the amount of luciferase activity produced by patient derived viruses in the presence of varying concentrations of the antiviral drug. By identifying the concentration of drug at which luciferase activity is half-maximum, the IC<sub>50</sub> of the virus from which patient-derived segment(s) were obtained for the antiretroviral agent can be determined. The IC50 provides a direct measure of the susceptibility of the HIV infecting the patient to raltegravir. </p><p id="p0170" num="0170"> In the susceptibility tests, packaging host (293) cells were seeded in 10-cm-diameter dishes and were transfected one day after plating with test vector plasmid DNA and the envelope expression vector. Transfections were performed using a calcium-phosphate co- precipitation procedure. The cell culture media containing the DNA precipitate was replaced with fresh medium, from one to 24 hours, after transfection. Cell culture medium containing viral particles comprising the RTV libraries was harvested one to four days after transfection and was passed through a 0.45-mm filter before optional storage at -80°C. Before infection, host cells (293 cells) to be infected were plated in cell culture media containing varying concentrations of raltegravir. Control infections were performed using cell culture media from mock transfections (no DNA) or transfections containing the test vector plasmid DNA without the envelope expression plasmid. One to three or more days after infection the media was removed and cell lysis buffer (Promega Corp.; Madison, WI) was added to each well. Cell lysates were assayed for luciferase activity. Alternatively, cells were lysed, and luciferase was measured by adding Steady-Glo (Promega Corp.; Madison, WI) reagent directly to each well without aspirating the culture media from the well. . The amount of 
<!-- EPO <DP n="51"/>-->
 luciferase activity generated in the infected cells was plotted as a function of the log of the concentration of raltegravir to determine the IC50 of the assayed HIV. </p><p id="p0171" num="0171"> Figure 4 is a graph showing the fold change (FC) in raltegravir (Ral) susceptibility of the seventy-six patient viruses having a single amino acid substitution at position 143 of integrase, as compared to the raltegravir susceptibility of an NL4-3 virus and determined by the PhenoSense<sup>®</sup> assay. Forty-four viruses had a Y143R substitution, and twenty-three had a Y143C substitution. Three viruses had a Y143G substitution (open square in the Y143HGS column); two viruses had a Y143H substitution (x in the Y143HGS column); and four viruses had a Y143S substitution (closed squares in the Y143HGS column). The amino acid substitution present in the virus is shown on the x-axis, and the fold change in IC50 of raltegravir relative to the reference virus IC50 is shown on the y-axis. </p><p id="p0172" num="0172"> Reductions in raltegravir susceptibility (fold change in IC<sub>50</sub> (FC)) exhibited by patient viruses with 143 substitutions varied from about 4-fold to greater than about 150-fold (i.e. , IC<sub>5</sub>o was not reached even at highest drug concentration tested). Large reductions in raltegravir susceptibility were exhibited by viral populations with a variety of substitutions at position 143, including Y143R/C/H/G/S. </p><p id="p0173" num="0173">EXAMPLE 3 </p><p id="p0174" num="0174"> Identification of Secondary Mutations in Integrase that Affect Raltegravir Susceptibility </p><p id="p0175" num="0175"> The integrase mutations of the six of the patient virus populations containing alternative substitutions at position 143 from Figure 4 were detected. Figure 5 is a table showing each of the mutations for each virus population, as well as the fold change (FC) in raltegravir susceptibility for each population, as compared to the raltegravir susceptibility of an NL4-3 virus and determined by the PhenoSense<sup>®</sup> assay. </p><p id="p0176" num="0176"> Y143C/H/G/S viruses contained more secondary mutations {e.g., L74I/M, E92Q,</p><p id="p0177" num="0177">T97A, E138K, G163R, I203M, and S230R) than Y143R viruses (Fig. 6). Figures 6A and 6B are graphs showing the number and type of secondary mutations present in patient viruses with various substitutions present at position 143 of integrase. In Figure 6A, the left bar in each pair of bars represents viruses that have an arginine present at position 143 of integrase, and the right bar in each pair represents viruses that have a cysteine, histidine, glycine, or serine residue present at position 143 of integrase. Figure 6A lists the number of secondary mutations present on the x-axis and the number of viruses on the y-axis. In Figure 6B, the left bar in each set represents viruses that have an arginine at position 143 of the integrase, 
<!-- EPO <DP n="52"/>-->
 the center bar in each set represents viruses that have a cysteine at position 143 of the integrase, and the right bar in each set represents viruses that have a cysteine, histidine, glycine, or serine residue present at position 143 of the integrase. Figure 6B shows the particular secondary mutation in integrase present on the x-axis versus the percentage of viruses on the y-axis. T97A was the most common secondary mutation for all Y143X viruses. L74I/M and S230R secondary mutations were more prevalent in Y143C/H/G/S viruses than Y143R viruses. The S230R mutation was identified in Y143C and Y143C/H/G/S viruses. </p><p id="p0178" num="0178"> Figure 7 is a table showing the frequency of secondary mutations among the seventy- six viruses identified with Y143R, Y143C, or Y143H/G/S mutations. The percentages shown in parentheses are with respect to the group (i.e. , the particular 143 mutation present). The average number of secondary mutations identified for each group is indicated in the far right, and the highest frequency of secondary mutations are indicated in bold font. The Y143C mutants had the highest average number of secondary mutations present. T97A and S230R were the most frequent secondary mutations present. </p><p id="p0179" num="0179"> The effects of the secondary mutations were evaluated using Y143C, a well-known substitution, as a backbone, and larger reductions in raltegravir susceptibility were found to require additional secondary mutations. Site directed mutant (SDM) viruses were created that had only the specific integrase mutation listed on the x-axis of Figure 8A, 8B, or 8C. Figures 8A, 8B, and 8C are graphs showing the fold change (FC) in raltegravir susceptibility of the SDM viruses, as compared to the raltegravir susceptibility of an NL4-3 virus and determined by the PhenoSense assay. Figure 8A shows the fold change in raltegravir susceptibility for viruses having a single amino acid substitution at position 143 of integrase (histidine, cysteine, serine, glycine, or arginine). Interestingly, all Y143 SDMs resulted in relatively small reductions in raltegravir susceptibility. Figure 8B shows the fold change in raltegravir susceptibility for viruses having a single amino acid substitution at position 143 of integrase (histidine, cysteine, serine, glycine, or arginine), plus a substitution of alanine at position 97 of integrase. Figure 8C shows the fold change in raltegravir susceptibility for viruses having a cysteine substitution at position 143 of integrase, plus one or more secondary mutations (at positions 97, 163, 203, 74, 230, or 92 of the integrase). Based on SDM susceptibility data, the Y143R mutation alone conferred a larger reduction in RAL susceptibility (FC=20) than the other Y143X substitutions (FC=3-6) (Figure 8 A). Addition of the T97A substitution to the Y143R substitution further decreased RAL susceptibility 
<!-- EPO <DP n="53"/>-->
 (FC=70), whereas addition of the T97A substitution to all other Y143X substitutions conferred modest reductions in RAL susceptibility (FC=7-16) (Figure 8B). </p><p id="p0180" num="0180"> Figure 9 shows results based on site directed mutant susceptibility data for single, double, and triple mutants. The substitution at position 143 of integrase is shown across the top of the table, and the total mutations present are shown in the first column. The values shown are the fold change in IC<sub>5</sub>o of the site directed mutant viruses. With respect to the single mutations at position 143, the Y143R mutation conferred a larger reduction in RAL susceptibility (FC=20) than the other Y143X substitutions (FC=3-6). With respect to the double mutants with Y143X plus one secondary mutation, addition of the T97A substitution to the Y143R substitution resulted in a large reduction in RAL susceptibility (FC=70) compared to all other Y143X substitutions (FC=7-16). Addition of S230R to Y143C/G/S conferred a further reduction in RAL susceptibility (FC=15-24), but addition of S230R to Y143R did not. With respect to triple mutants with Y143X and T97A plus an additional secondary mutation, introduction of S230R conferred the greatest reduction in RAL susceptibility among all secondary mutations analyzed, especially for Y143C/G/S. </p><p id="p0181" num="0181"> Taken together, these data clearly indicate that secondary mutations in integrase sequences contribute to larger reductions in raltegravir susceptibility for many patient viruses, when present in addition to Y143 mutations. The observed genetic profiles and Ral susceptibility measurements are consistent with the prevalence of amino acid substitutions at integrase position 143 and define the selective advantage of Ral primary and secondary mutations. </p><p id="p0182" num="0182">EXAMPLE 4 </p><p id="p0183" num="0183"> HIV Replication Capacity Assays </p><p id="p0184" num="0184"> Replication capacity tests performed with test vectors were carried out using packaging host and target host cells consisting of the human embryonic kidney cell line 293. Replication capacity tests were carried out with the RTV libraries by using viral particles comprising the RTV libraries to infect a host cell in which the expression of the indicator gene is measured. The amount of indicator gene (luciferase) activity detected in infected cells is used as a direct measure of "infectivity," i.e. , the ability of the virus to complete a single round of replication. Thus, the amount of luciferase activity observed in the infected cells in the presence or absence of Ral provides a direct measurement of the replication capacity of the virus under these two conditions. Thus, replication capacity can be used to assess the 
<!-- EPO <DP n="54"/>-->
 extent to which one or more mutations impairs the ability of the virus to replicate in the absence of drug or conversely improves the ability of the virus to replicate in the presence of drug. By determining the amount of luciferase activity, the replication capacity of the virus from which patient-derived segment(s) were obtained for the antiretroviral agent can be determined. The amount of luciferase activity observed can also be compared to the amount of luciferase activity observed for a control assay performed with a reference viral segment, such as an viral segment obtained from a reference virus such as, for example, NL4-3 or MB. When such comparisons are performed, the replication capacity of the virus or viral population can be reported as a percentage of the replication capacity observed for the reference virus. </p><p id="p0185" num="0185"> In the replication capacity tests, packaging host (293) cells were seeded in 10-cm- diameter dishes and were transfected one day after plating with test vector plasmid DNA and the envelope expression vector. Transfections were performed using a calcium-phosphate co- precipitation procedure. The cell culture media containing the DNA precipitate was replaced with fresh medium, from one to 24 hours, after transfection. Cell culture medium containing viral particles comprising the TV libraries was harvested one to four days after transfection and was passed through a 0.45-mm filter before optional storage at -80°C. Before infection, host cells (293 cells) to be infected were plated in cell culture media. Control infections were performed using cell culture media from mock transfections (no DNA) or transfections containing the test vector plasmid DNA without the envelope expression plasmid. One to three or more days after infection, the media was removed and cell lysis buffer (Promega Corp.; Madison, WI) was added to each well. Cell lysates were assayed for luciferase activity. Alternatively, cells were lysed and luciferase was measured by adding Steady-Glo (Promega Corp.; Madison, WI) reagent directly to each well without aspirating the culture media from the well. The amount of luciferase activity produced in infected cells was normalized to adjust for variation in transfection efficiency in the transfected host cells by measuring the luciferase activity in the transfected cells, which is not dependent on viral gene functions, and adjusting the luciferase activity from infected cell accordingly. </p><p id="p0186" num="0186"> In the absence of Ral, the replication capacity of the Y143R site directed mutant (SDM) (78%) was greater than the replication capacity of the other Y143X SDMs (41 -59%). </p><p id="p0187" num="0187"> Figures 10A, 10B, IOC, and 10D are graphs showing the effect of Y143 mutations with or without secondary mutations on viral fitness or replication capacity of the viruses. Each graph shows the serial drug dilution from low to high concentration on the x axis 
<!-- EPO <DP n="55"/>-->
 plotted against the ratio of relative luciferase units (RLU) of the mutant (MT) to the wild type (WT) virus on the y axis. The mutations present in the integrase are indicated (Y143C (diamonds), Y143H (gray asterisks), Y143G (gray triangles), Y143R (black triangle), and Y143S (black asterisks)). Panel A shows the viral fitness of viruses with single mutations at Y143. Panels B, C, and D show the viral fitness of viruses with mutations at Y143 as well as one or more secondary mutation (T97A (Panel B), S230R (Panel C), or both T97A and S230R (Panel D)). Viruses comprising the Y143X and T97A mutations exhibited a decrease in viral replication capacity. </p><p id="p0188" num="0188">EXAMPLE 5 </p><p id="p0189" num="0189"> Cross-Resistance of HIV to Raltegravir and Elvitegravir </p><p id="p0190" num="0190"> The susceptibility of HIV to elvitegravir was analyzed as described in detail for raltegravir (See, e.g., Example 2). The results of the susceptibility analysis for both elvitegravir and raltegravir are shown in Figure 1 1. </p><p id="p0191" num="0191"> Figures 11A and 1 I B are graphs showing the cross-resistance pattern of patient- derived viruses to raltegravir (RAL) and elvitegravir (EVG). In Figure 11 A, the fold change in raltegravir susceptibility (RAL FC, x axis) is plotted against the fold change in elvitegravir susceptibility (EVG FC, y axis). In Figure 1 IB, the fold change decrease in susceptibility (FC in IC<sub>5</sub>0) was plotted for both RAL and EVG as shown. </p><p id="p0192" num="0192"> While the invention has been described and illustrated with reference to certain embodiments thereof, those skilled in the art will appreciate that various changes, modifications and substitutions can be made therein without departing from the spirit and scope of the invention. All patents, published patent applications, and other non-patent references referred to herein are incorporated by reference in their entireties. 
</p></description><claims mxw-id="PCLM44726054" ref-ucid="WO-2012116371-A1" lang="EN" load-source="patent-office"><claim-statement><!-- EPO <DP n="56"/>-->CLAIMS </claim-statement><claim id="clm-0001" num="1"><claim-text>1. A method for determining the susceptibility of a human immunodeficiency virus (HIV) to an integrase inhibitor, comprising detecting in a biological sample from a patient infected with HIV a nucleic acid encoding an HIV integrase that comprises a mutation at codon 143, wherein the mutation at codon 143 does not encode arginine (R) or cysteine (C), and wherein the presence of the integrase-encoding nucleic acid in the biological sample indicates that the patient's HIV has a decreased susceptibility to the integrase inhibitor relative to a reference HIV, thereby assessing viral susceptibility to the integrase inhibitor. </claim-text></claim><claim id="clm-0002" num="2"><claim-text>2. The method of Claim 1 , wherein the integrase inhibitor is raltegravir or elvitegravir. </claim-text></claim><claim id="clm-0003" num="3"><claim-text>3. The method of Claim 1, wherein the mutation at codon 143 encodes a histidine (H), glycine (G), or serine (S). </claim-text></claim><claim id="clm-0004" num="4"><claim-text>4. The method of Claim 3, wherein the mutation at codon 143 encodes a histidine (H) residue. </claim-text></claim><claim id="clm-0005" num="5"><claim-text>5. The method of Claim 3, wherein the mutation at codon 143 encodes a glycine (G) residue. </claim-text></claim><claim id="clm-0006" num="6"><claim-text>6. The method of Claim 3, wherein the mutation at codon 143 encodes a serine (S) residue. </claim-text></claim><claim id="clm-0007" num="7"><claim-text>7. The method of Claim 1, wherein the nucleic acid further comprises a mutation at codon 72, codon 74, codon 92, codon 97, codon 138, codon 157, codon 163, codon 203, codon 230, or a combination thereof. </claim-text></claim><claim id="clm-0008" num="8"><claim-text>8. The method of Claim 7, wherein the nucleic acid comprises a mutation at codon 143 and one mutation at codon 72, codon 74, codon 92, codon 97, codon 138, codon 157, codon 163, codon 203, or codon 230. </claim-text></claim><claim id="clm-0009" num="9"><claim-text>9. The method of Claim 7, wherein the nucleic acid comprises a mutation at codon 143 and a mutation at two or more of codon 72, codon 74, codon 92, codon 97, codon 138, codon 157, codon 163, codon 203, and codon 230. </claim-text></claim><claim id="clm-0010" num="10"><claim-text>10. The method of Claim 7, wherein the mutation at codon 72 encodes an isoleucine (I) residue. <!-- EPO <DP n="57"/>--> </claim-text></claim><claim id="clm-0011" num="11"><claim-text>1 1. The method of Claim 7, wherein the mutation at codon 74 encodes a methionine (M) or isoleucine (I) residue. </claim-text></claim><claim id="clm-0012" num="12"><claim-text>12. The method of Claim 7, wherein the mutation at codon 92 encodes a glutamine (Q) or leucine (L) residue. </claim-text></claim><claim id="clm-0013" num="13"><claim-text>13. The method of Claim 7, wherein the mutation at codon 97 encodes an alanine (A) residue. </claim-text></claim><claim id="clm-0014" num="14"><claim-text>14. The method of Claim 7, wherein the mutation at codon 138 encodes an aspartic acid (D) residue. </claim-text></claim><claim id="clm-0015" num="15"><claim-text>15. The method of Claim 7, wherein the mutation at codon 157 encodes a glutamine (Q) residue. </claim-text></claim><claim id="clm-0016" num="16"><claim-text>16. The method of Claim 7, wherein the mutation at codon 163 encodes an arginine (R) residue. </claim-text></claim><claim id="clm-0017" num="17"><claim-text>17. The method of Claim 7, wherein the mutation at codon 203 encodes a methionine (M) residue. </claim-text></claim><claim id="clm-0018" num="18"><claim-text>18. The method of Claim 7, wherein the mutation at codon 230 encodes an arginine (R) residue. </claim-text></claim><claim id="clm-0019" num="19"><claim-text>19. The method of Claim 1 , wherein the reference HIV is an HXB-2, NL4-3, IIIB, or SF2 population. </claim-text></claim><claim id="clm-0020" num="20"><claim-text>20. A method for determining the susceptibility of a human immunodeficiency virus (HIV) to an integrase inhibitor, comprising detecting in a biological sample from a patient infected with HIV a nucleic acid encoding an HIV integrase that comprises a mutation at codon 143, wherein the mutation at codon 143 does not encode arginine (R) or cysteine (C), and a mutation at codon 74 or codon 97, wherein the presence of the integrase-encoding nucleic acid in the biological sample indicates that the patient's HIV has a decreased susceptibility to the integrase inhibitor relative to a reference HIV, thereby assessing viral susceptibility to the integrase inhibitor. </claim-text></claim><claim id="clm-0021" num="21"><claim-text>The method of Claim 20, wherein the integrase inhibitor is raltegravir or elvitegravir. <!-- EPO <DP n="58"/>--> </claim-text></claim><claim id="clm-0022" num="22"><claim-text>22. The method of Claim 20, wherein the mutation at codon 143 encodes a histidine (H), glycine (G), or serine (S). </claim-text></claim><claim id="clm-0023" num="23"><claim-text>23. The method of Claim 22, wherein the mutation at codon 143 encodes a histidine (H) residue. </claim-text></claim><claim id="clm-0024" num="24"><claim-text>24. The method of Claim 22, wherein the mutation at codon 143 encodes a glycine (G) residue. </claim-text></claim><claim id="clm-0025" num="25"><claim-text>25. The method of Claim 22, wherein the mutation at codon 143 encodes a serine (S) residue. </claim-text></claim><claim id="clm-0026" num="26"><claim-text>26. The method of Claim 20, wherein the mutation at codon 74 encodes a methionine (M) or isoleucine (I) residue. </claim-text></claim><claim id="clm-0027" num="27"><claim-text>27. The method of Claim 20, wherein the mutation at codon 97 encodes an alanine (A) residue. </claim-text></claim><claim id="clm-0028" num="28"><claim-text>28. The method of Claim 19, where the integrase-encoding nucleic acid comprises a mutation at both codon 74 and codon 97. </claim-text></claim><claim id="clm-0029" num="29"><claim-text>29. A method for determining the susceptibility of a human immunodeficiency virus (HIV) to an integrase inhibitor, comprising detecting in a biological sample from a patient infected with HIV a nucleic acid encoding an HIV integrase that comprises a mutation at codon 143, wherein the mutation at codon 143 does not encode arginine (R) or cysteine (C), and a mutation at codon 230, wherein the presence of the integrase-encoding nucleic acid in the biological sample indicates that the patient's HIV has a decreased susceptibility to the integrase inhibitor relative to a reference HIV, thereby assessing viral susceptibility to the integrase inhibitor. </claim-text></claim><claim id="clm-0030" num="30"><claim-text>30. The method of Claim 29, wherein the integrase inhibitor is raltegravir or elvitegravir. </claim-text></claim><claim id="clm-0031" num="31"><claim-text>31. The method of Claim 29, wherein the mutation at codon 143 encodes a histidine (H), glycine (G), or serine (S). </claim-text></claim><claim id="clm-0032" num="32"><claim-text>32. The method of Claim 31 , wherein the mutation at codon 143 encodes a histidine (H) residue. <!-- EPO <DP n="59"/>--> </claim-text></claim><claim id="clm-0033" num="33"><claim-text>33. The method of Claim 31 , wherein the mutation at codon 143 encodes a glycine (G) residue. </claim-text></claim><claim id="clm-0034" num="34"><claim-text>34. The method of Claim 31 , wherein the mutation at codon 143 encodes a serine (S) residue. </claim-text></claim><claim id="clm-0035" num="35"><claim-text>35. The method of Claim 29, wherein the mutation at codon 230 encodes an arginine (R) or asparagine (N) residue. </claim-text></claim><claim id="clm-0036" num="36"><claim-text>36. The method of Claim 29, wherein the nucleic acid further comprises a mutation at codon 97. </claim-text></claim><claim id="clm-0037" num="37"><claim-text>37. The method of Claim 33, wherein the mutation encodes an alanine (A) residue. </claim-text></claim><claim id="clm-0038" num="38"><claim-text>38. A method for determining the replication capacity of a human immunodeficiency virus (HIV), comprising detecting in a biological sample from a patient infected with HIV a nucleic acid encoding an HIV integrase that comprises a mutation at codon 143, wherein the mutation at codon 143 does not encode arginine (R) or cysteine (C), and a mutation at codon 97, wherein the presence of the integrase-encoding nucleic acid in the biological sample indicates that the patient's HIV has a decreased replication capacity relative to a reference HIV, thereby assessing viral replication capacity. </claim-text></claim><claim id="clm-0039" num="39"><claim-text>39. The method of Claim 38, wherein the mutation at codon 143 encodes histidine (H), glycine (G), or serine (S). </claim-text></claim><claim id="clm-0040" num="40"><claim-text>40. The method of Claim 38, wherein the mutation at codon 97 encodes an alanine (A) residue. </claim-text></claim><claim id="clm-0041" num="41"><claim-text>41. A method for determining the selective advantage of an integrase mutation or mutation profile, comprising: </claim-text><claim-text> determining the number of nucleotide substitutions in an integrase-encoding nucleic acid at codon 143 that are required to convert the codon encoding tyrosine to a codon encoding arginine, cysteine, histidine, glycine, or serine; </claim-text><claim-text> determining the reduction in susceptibility to an integrase inhibitor that is conferred by the amino acid substitution at position 143; </claim-text><claim-text> determining the impact of amino acid substitutions at position 143 on replication capacity; <!-- EPO <DP n="60"/>--> determining the number of secondary mutations and their impact on susceptibility to the integrase inhibitor, on replication capacity, or on both susceptibility to the integrase inhibitor and replication capacity; and </claim-text><claim-text> determining the selective advantage for the mutation or mutation profile, wherein the fewer the number of nucleotide substitutions required for the amino acid substitution, the higher the reduction of the susceptibility to the integrase inhibitor, the lower the impact on replication capacity, and the fewer the number of secondary mutations required to achieve the reduction in susceptibility to the integrase inhibitor, the greater the selective advantage for the mutation or mutation profile, thereby determining the selective advantage for the mutation or mutation profile. </claim-text></claim><claim id="clm-0042" num="42"><claim-text>42. The method of Claim 38, wherein the integrase inhibitor is raltegravir or elvitegravir. </claim-text></claim></claims><copyright>User acknowledges that Fairview Research LLC and its third party providers retain all right, title and interest in and to this xml under applicable copyright laws.  User acquires no ownership rights to this xml including but not limited to its format.  User hereby accepts the terms and conditions of the Licence Agreement</copyright></patent-document>
